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1. Introduction 
1.1 Glioma  
 
Gliomas are brain tumors originated from glial cells1, which are non-neuronal cells whose 
main functions are myelin formation, support and maintenance of neurons. Glial cells can 
be grouped in microglia and macroglia2.  
Microglia are specialized macrophages derived from hematopoietic precursors localized 
on the brain. They originate from the ectodermal layer and have a large and star-like 
morphology. Their principal function is to phagocytose damaged neurons and glial cells. 
Macroglia are subdivided into three principle types, namely astrocytes, oligodendrocytes 
and ependymal cells. Each of them has special functions:  
 
• Astrocytes: the provision of nutrients, oxygen, and mechanical support; the 
development guidance, waste disposal and immune functions.  
• Oligodendrocytes: the production of myelin sheath, a modified plasma membrane 
surrounding the nerve axon, enhancing the efficiency of electrical signal 
propagation. 
• Ependymal cells: create and secrete cerebrospinal fluid (CSF) and assist in their 
circulation through the brain ventricles and the spinal cord 3. 
 
Glial cells divide and multiply by asymmetric cell division. When the control of this 
ability is lost, the formation of gliomas takes place. Astrocytomas are tumors derived 
from astrocytes and constitute 75% of all gliomas4. Other less common types of gliomas 
are oligodendroglioma (9%) and ependymoma (6%), which originate from 
oligodendrocytes and ependymal cells, respectively 5,6. Tumors derived from mixed cell 
types constitute the remaining cases. Traditionally, astrocytomas have been subdivided 
depending on their malignancy grade. An established histological grading created by the 
World Health Organization (WHO) assigned grades from I to IV, with I being the least 
aggressive and IV being the most aggressive5. 
The updated classification of the WHO is based on morphology, molecular and genetical 
factors of astrocytomas. Two of the principal changes on the updated WHO classification 
is the incorporation of Isocytrate Dehydrogenase (IDH) mutations, and a characteristic 
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translocation of the p arm of chromosome 1 with the arm of chromosome 19 (1p/19q 
codeletion) as important factors for the subdivision of gliomas 7,8. 
Astrocytomas with IDH mutations show no 1p/19q codeletion, whereas 
oligodendriogliomas carries both IDH mutation and 1p/19q codeletion. Astrocytomas 
with no IDH mutation (IDH wild-type) show a worse prognosis in comparision with 
astrocytomas with IDH mutations (Figure 1.1)7,8. 
 
 
Figure 1.1 Astrocytoma classification in the updated 2016 Central Nervous System WHO 
classification (adapted from Johnson et al., 2016)8.  
 
1.2 Glioblastomas 
 
The highest-grade astrocytoma, the glioblastoma multiforme (GBM, astrocytoma WHO 
grade IV) is the most common and most aggressive nervous system tumor. It can be 
divided in primary and secondary GBM. The “primary” (de novo) GBMs are common 
and display no signs of a preceding low-grade tumor. They develop predominantly in 
elderly patients 5,9. In contrast, secondary GBMs develop in younger patients through 
progression from lower-grade diffuse astrocytoma (WHO grade II) or anaplastic 
astrocytoma (WHO grade III)5,10. 
 
The current treatment for GBM patients consists of surgery, radiotherapy and 
chemotherapy. Complete surgical resection is practically impossible. Radiotherapy in 
combination with the adjuvant temozolomide (TMZ) represents the standard treatment for 
newly diagnosed GBM and the overall survival after 5 years of diagnosis is less than 5% 
6,11.  
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1.2.1 Molecular basis for the development of GBMs  
 
Genetic alterations are commonly assumed to be the basis of tumor development. These 
mutational events trigger the activation of genes related to tumor formation (oncogenes) 
or the silencing of tumor suppressor genes9. Several mutations, for example TP53, 
PDGFRA, EGFR, and NF1, have been described in the context of GBM development 12.  
Depending of the subtype of GBM, the presence of IDH1 mutations varies. IDH1 
mutations are more frequent (80%) in secondary GBMs, progressed from anaplastic 
astrocytomas, whereas in primary GBMs the incidence of this mutation is only 5% 
13,1415,16. The small fraction of primary GBMs with IDH1 mutations is only found in 
younger patients 13,17.  
Interestingly, a rare fraction of secondary GBMs lacks IDH1 mutations. These GBMs 
have progressed from grade III glioma, while the majority of secondary GBMs, that 
exhibit IDH1 mutations, have developed from grade II gliomas15. 
Remarkably, IDH mutations do not result in a complete loss of function as only one IDH1 
gene copy is altered. This specific mutation leads to a single amino acid exchange, 
namely arginine 132 to histidine, in the IDH1 active site 18. 
 
The updated WHO classification, incorporate the traditional “primary” and “secondary” 
glioblastomas classification into two new subtypes based on the presence of IDH 
mutations 7.  
 
Table 1.1 Glioblastoma classification based on the presences of IDH mutation 8.  
Glioblastoma, IDH Mutant Glioblastoma, IDH Wild-type 
10 % of GBMs 90% of GBMs 
Younger median age Older median age 
Good Prognosis Poor Prognosis 
Secondary GBMs Primary GBMs 
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1.3 Glioblastoma and metabolism  
 
Several imaging studies used in brain tumor diagnosis have their basis in the metabolic 
activity of tumor cells.  
Positron emission tomography (PET) is an imaging technology that is able to detect and 
characterize tumors based on their molecular and biochemical properties, as it is the case 
of glucose uptake, nucleoside or amino acid metabolism. During a PET scan a small 
amount of e.g. radioactive glucose is injected, which is uptaken by the tumor cells 
depending on malignancy19,20. Studies with fluoro-2-deoxyglucose (18F-FDG) have 
demonstrated differences in 18F-FDG uptaking between brain tumor subtypes, being 
higher in GBM than in meningioma or surrounding gray matter 21,22.  
Analogical, studies with amino acid tracers focus principally on 11C-methionine 23 and the 
thymidine analog 3´-18F-fluorothymidine (18F-FLT) to track the proliferation of brain 
tumors in vivo 24. Amino acid imaging is based on the observation that amino acid 
transport is generally increased in cells undergoing malignant transformation 25.  
 
1.3.1 Warburg Effect  
 
Otto Warburg observed that cancer cells present an altered glucose metabolism compared 
with non-cancerous cells26. Warburg demonstrated that cancer cells displayed an increase 
in their glycolytic activity, taking up glucose and producing higher levels of lactic acid 
even in the presence of sufficient levels of oxygen, which would allow energy production 
via oxidative phosphorylation (OXPHOS)27.  
Glycolysis is a sequence of chemical reactions where one molecule of glucose is 
converted into two molecules of pyruvate; these reactions occur in the cytosol of the cell. 
The overall energy release from this process is two ATP and two NADH molecules per 
molecule of glucose 28. Pyruvate is further metabolized into acetyl-CoA, which enters the 
mitochondrial matrix where the tricarboxic acid cycle (TCA) takes place. In contrast, in 
cancer cells high amounts of glucose are taken up and metabolized to pyruvate, but 
instead of entering into the TCA, most of the pyruvate is converted to lactate, which later 
is secreted from the cell 29. It has been reported that “aerobic” glycolysis supports tumor 
growth and proliferation due to fast generation of ATP and biomolecules 30,31. 
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Warburg considered that the functions of mitochondria were impaired in cancer cells; 
nevertheless several studies observed that in many cancer types, mitochondrial oxidative 
phosphorylation is intact 32–35.  
The Warburg effect has been associated with several oncogenic factors, which include 
HIF-1, MYC, GTP-binding proteins, RAS, tyrosine kinase pathway, p53 and IDH 
mutations 30,36.  
1.3.2. Isocitrate dehydrogenase (IDH) and tumor cell metabolism  
IDH is an important enzyme of the TCA. Three isozymes of IDH are known in humans: 
IDH1, IDH2 and IDH3. These isozymes are encoded by five genes: IDH1, IDH2, IDH3A, 
IDH3B and IDH3G37. All isozymes are metabolic enzymes that catalyze the 
interconversion of isocitrate into alpha-ketoglutarate (α-KG). IDH1 is located in the cell 
cytoplasm and peroxisomes, whereas IDH2 and IDH3 are found in the mitochondrial 
matrix37.  
α-KG is a ketone, which can be generated via glutaric acid from glutamine, and is 
involved in nitrogen transportation, oxidation reactions, and amino acid formation37. 
Mutated IDH gains the new ability to convert α-KG into D-2-hydroxyglutarate (D-HG) 
38,39. IDH mutations have not only been described in glioblastoma but also in other tumor 
entities such as acute myeloid leukemia 40. D-HG can be detected in culture supernatants 
of mutant cells and acute myeloid leukemia patient sera41. It has been reported that the 
serum HG levels did not differ between IDH1/2 allelic variants. In addition to this, high 
HG levels were also detected in some patients without IDH mutations in acute myeloid 
leukemia and thyroid carcinoma41. Importantly, high concentrations of HG predicted 
shorter overall survival in patients with acute myeloid leukemia 42. In contrast, patients 
with malignant gliomas and anaplastic astrocytomas that harbor IDH mutations show 
improved survival in comparison with patients whose tumors lack these mutations 43,44.  
The presence of HG in cell lines that lack IDH mutations raises the question what 
mechanism leads to HG production in these cells. In conditions of hypoxia, mitochondrial 
glutamate levels are high, favoring the reverse TCA reaction, a process replenished 
through glutaminolysis. In this case glutamine is converted into glutamate, which 
subsequently is metabolized into α-KG by glutamate dehydrogenase (GDH). Then IDH 
converts α-KG into isocitrate using NADP+ as an electron acceptor leading to the 
production of NADPH. Isocitrate is further metabolized to acetyl-CoA for lipid 
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metabolism 45. This inverse catalytic reaction by IDH has been reported in a SF188 
glioblastoma cell line under hypoxic conditions, along with an increase in HG levels46.  
In line with these results, high levels of cellular HG have been reported to drive the 
hydroxylation of HIF-1α, leading to decreased HIF expression and increased glioma 
transformation. Additionally, HG has been reported to competitively inhibit α-KG binding 
to several histone demethylases, including JmjC-domain-containing histone demethylase 
proteins (JHDM) leading to a widely aberrant histone methylation profile. Furthermore, 
HG is an inhibitor of hydroxymethylases TET methylcytosine dioxygenases (TET) 1 and 
2, enzymes that catalyze the conversion of methylcytosine to 5-hydroxymethylcytosine, 
inducing DNA demethylation. The epigenetic dysregulation caused by altered levels of 
HG and α-KG in IDH1 and IDH2 mutant cells may contribute to aberrant regulation of 
gene expression in cancer47 (See Figure 1.2). 
 
 
Figure 1.2. The role of IDH in metabolism of gliomas. The figure shows schematically that 
mutated IDH1 enzyme gains the ability to produce HG from α-ketoglutarate; this could lead to 
HIF stabilization through impairment of PHD activity. The stabilization of HIF promotes cell 
survival. In addition, the buildup of HG in IDH1- and IDH2-mutated cells has been linked to 
epigenetic changes through the inhibition of TET and JHDMs 48. Abbreviations: isocitrate 
dehydrogenase (IDH), hypoxia inducible factor (HIF), formate dehydrogenase (FDH), ten-eleven 
translocation (TET), prolyl hydroxylase domain (PHD), succinate dehydrogenase (SDH). Adapted 
from Gupta et al., 201148.  
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1.4 The role of tumor stroma in malignant gliomas 
 
T cells have been reported to infiltrate gliomas, and could be linked with an survival 
improval in patients with malignant gliomas 49,50. Genome microarray analysis supported 
the theory that host immunity can control tumor growth of high-grade gliomas. T cell-
associated genes were shown to be enriched in high-grade astrocytoma from long-term 
versus short-term survivors51. 
High intratumoral numbers of CD4+ and CD8+ T cells have been related with prolonged 
survival in other tumor entities. In melanoma, CD4+ T cells has been proved to control 
tumor invasion and metastasis 52, whereas in hepatic metastases of colorectal cancer high 
intra-tumoral CD8+ T cell infiltration predict better response to chemotherapy and 
prolonged survival 53. Interestingly, in renal cell carcinoma as well as in head and neck 
cancers T cell infiltration seems to be controlled by the metabolic phenotype of the tumor, 
as an accelerated glucose metabolism was shown to be associated with a low CD8 
effector T cell infiltration 54. 
Fibroblasts are an heterogenous population of stromal cells, with multiple functionalities, 
as wound-healing regulation, immune modulators production (growth factors, cytokines, 
chemokines) and play an important role in chronic inflammation 55. Numerous reports 
have identified stromal fibroblasts as important players in the induction of angiogenesis 
and metastasis in brain tumors 56,57, and tumor-associated macrophages are involved in 
fibroblast recruitment 58,59. The interaction of these stromal cells with brain tumor cells 
induced the production and activation of matrix metalloproteinase leading to glioma 
progression 60–64. Microglia cells/ macrophages play also an important role in the 
production of cytokines, particularly IL-10 65. The expression levels of IL-10 can 
significantly be related with tumor cell proliferation, migration and the promotion of 
metastasis in gliomas 66,67. The expression of proinflammatory cytokines in glioblastomas 
is associated with typical immune signaling cascades as is the case of p38 MAPK; an 
inhibition on p38 MAPK cascade results in the incapacity of glioma cells to metastasize 68.  
1.5 Immune biology 
 
The immune system is a complex interactive network of cells, humoral factors and 
cytokines. The principal function is the host’s protection from harmful environmental 
agents 69. 
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The immune response is divided into two types of responses, determined by the speed and 
specificity of the reaction. These responses are innate and adaptive immunity 70. 
1.5.1 Innate Immunity 
 
The innate immunity is the faster reaction against infectious agents. The main components 
of this type of response are: 1) physical, chemical, and microbiological barriers, 2) 
phagocytes (neutrophils, monocytes, macrophages and dendritic cells (DCs)), 3) acute 
phase proteins, 4) complement factors, and 5) natural killer cells 69,70.  
This type of immunity occurs in the same magnitude all the time regardless of repeated 
encounters with the infectious agent 71.  
 
The primary function of mononuclear phagocytes, like monocytes, macrophages and DCs, 
is phagocytosis. Phagocytosis is defined as the engulfment of antigens, a process in which 
a remodelling of actin is necessary, leading to the formation of the so-called phagosome. 
Phagocytic macrophages manage the defense against bacteria via surface receptors, which 
are able to recognize and bind several components of bacterial surfaces. The binding of 
bacterial molecules to the surface receptors of phagocytic macrophages induces the 
absorption of the bacterium and the secretion of biological active molecules, such as 
cytokines. This leads to a cell to-cell communication during the immune responses and 
promotes the migration of cells towards sites of inflammation, infection and trauma 72–74.  
In the central nervous system, monocyte-derived macrophages are called microglial cells 
70. Several studies investigated monocytes as an important component of the glioblastoma 
microenvironment. GBM cells attract circulating monocytes to the tumor parenchyma, 
where these monocytes adopt immunosuppressive properties 75–78.  
1.5.2 Adaptive Immunity  
 
The adaptive immunity is composed of different types of lymphocytes, namely B cells 
and T cells, which are capable of reacting highly specific to foreign antigens. In addition, 
the adaptive immunity is able to “remember” infectious agents due to the induction of so-
called “memory” cells. This leads to a faster response upon secondary exposure of the 
infectious agent 70.  
B cells are capable of producing antibodies. They recognize extracellular antigens and 
differentiate into antibody-secreting plasma cells. T lymphocytes recognize antigens 
presented on MHC molecules via their specific T cell receptor (TCR). There are different 
types of T lymphocytes: CD4+ helper T cells, CD8+ cytotoxic T cells (CTLs) and 
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regulatory T cells. The CD4+ helper T cells secrete cytokines in response to an antigenic 
stimulation and thereby activate macrophages, DCs or other T cells. Cytotoxic CD8+ T 
cells are responsible for the killing of virus-infected cells and can also destroy tumor cells. 
In contrast, regulatory T cells represent “the brake” of the immune system and can inhibit 
activated CD4+ T cells 70, CD8+ T cells and B cells, thereby limiting the immune response 
79.  
1.5.3 Antigen Presenting Cells (APCs) 
 
Antigen presenting cells (APCs) are a heterogeneous group of immune cells that mediate 
the cellular immune response by taking up, processing and presenting antigens to T 
lymphocytes. The principal APCs in the immune system are dendritic cells (DCs), 
macrophages, and B cells.  
APCs capture infectious antigens through several mechanisms: 
• receptor-mediated endocytosis 
• pinocytosis  
• phagocytosis  
As previously mentioned, phagocytosis is based in the remodelling of actin and the 
formation of a phagosome. Recent studies have shown that phagosome maturation is 
regulated by signals originating from pattern recognition receptors discriminating between 
self and non-self antigens 80.  
1.5.3.1 Dendritic cells 
 
Dendritic cells (DCs) are the most potent APCs of the immune system and act as link 
between innate and adaptive immunity 81. To become potent T cell stimulators, DCs have 
to mature. This process is accompanied by functional and phenotypic changes.  
DCs are competent inducers of B and T cell responses 82,83. TCRs recognize peptides 
attached to molecules of the major histocompatibility complex (MHC) on the surface of 
APCs. There are two types of MHC: MHC class I and MHC class II, which stimulate 
CTLs and helper T cells, respectively 82.  
DCs capture and process antigens, and display large amounts of MHC-peptide complexes 
at their surface. In contrast, the amounts of antigen-MHC complexes and costimulatory 
molecules on tumours are often small. 
Introduction 
10 
 
Immature DCs (iDCs) are unable to stimulate T cells due to the absence of costimulatory 
signals such as CD40, CD54 and CD86 that are needed for proper T cell activation. 
Nevertheless, iDCs are able of capturing and processing antigens to form MHC peptide 
complexes. iDCs show large amounts of MHC class II-rich compartments (MIICs), which 
are endosomal structures, that include HLA-DM or H-2M, which enhance and rearrange 
peptide binding to MHC class II molecules83–87.  
iDCs reside in peripheral tissues until they are exposed to inflammatory stimuli and take 
up antigen. After being stimulated, iDCs migrate to the peripheral lymph nodes where 
they mature and express additional molecules that induce T cell stimulation 83. Mature 
DCs (mDCs) produce high levels of IL-12 88–90, a cytokine that enhances both innate and 
adaptive immunity. During the maturation process the expression of co-stimulatory 
molecules such as CD83, CD80 and CD86 is upregulated 91. Maturation can be influenced 
by diverse factors: bacteria, microbial cell wall components like lipopolysaccharide 
(LPS)84, and cytokines like IL-1, GM-CSF, and TNF-α. In contrast, IL-10 inhibits the 
maturation process 92.  
To generate anti-tumoral immune responses, APCs have to present peptides bound to 
MHC molecules. Mature and functional active DCs seem to be absent in many tumour 
types, resulting in a failure in the generation of a tumor-specific T cell response; a 
possible underlying mechanism is the accumulation of immunosuppressive factors such as 
IL-10, TGF-ß and vascular endothelial growth factor in the tumor environment, that 
reduce DC development and function 83,93.  
1.5.4 Cytokines 
 
Cytokines are a group of proteins involved in the regulation of the innate and adaptive 
immunity. Their synthesis is induced by cellular activation, differentiation and 
proliferation signals of immune cells 70.  
Mononuclear phagocytes are mainly stimulated by bacterial compounds and secrete 
inflammatory cytokines like tumor necrosis factor alpha (TNF-α), IL-6 and IL-1. As a 
feedback regulation mononuclear phagocytes can also produce anti-inflammatory 
cytokines like IL-10, which suppress the immune response; for example the production of 
TNF-α is inhibited by IL-10 94.  
IL-6 is secreted by macrophages and T cells and is able to cross the blood brain barrier 95. 
It mediates pro-inflammatory and anti-inflammatory responses 96.  
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After stimulation, DCs produce IL-12. IL-12 is a prerequisite for the initiation of a CD4+ 
T helper 1 (TH1) response, which consequently activates CTLs. IL-10 counteracts the 
effects of IL-12 70. A reduction in the production of IL-12 and IFN-γ has been related with 
the inhibition of tumor- infiltrating T cells in ovarian cancer 97.  
1.5.4.1 IL-12 regulations 
 
iDCs become activated through the stimulation of their pattern-recognition receptors 
(PRRs). In this context, toll like receptors (TLR) play a crucial role in the activation of 
DCs. Ten functional TLRs have been identified in humans 98. Each TLR detects specific 
molecular structures of pathogens as their ligand (pathogen-associated molecular patterns 
(PAMPs)) 72. After the ligand binds to its typical TLR, pro-inflammatory activities take 
place 99. All TLRs but TLR3, bind to the adaptor protein myeloid differentiation primary-
response protein (MyD88) 100.  
 
TLR4 is localized on the cell surface and is generally stimulated by LPS, the cell wall 
component of Gram-negative bacteria. In the serum, LPS is connected to LPS-binding 
Protein (LBP) which interacts with a receptor complex of TLR4, CD14 and associated 
proteins 101. After stimulation, signalling cascades (see figure 1.3), mediated by TLR4, 
modulate gene expression and subsequently the production of several pro-inflammatory 
cytokines such as IL-6, TNF-α and IL-12. IL-12 production is modulated mainly under 3 
different pathways, each one with their own kinetics. 
 
Pathway 1 “Canonical Pathway”  
This pathway consists in a series of phosphorylations of IκB proteins by a multiple IκB 
kinases complex (IKK complex), which consists of two catalytic components (IKKα and 
IKKβ) and a regulatory component (IKKγ)102. After the phosphorylation of IκB proteins, 
IκB is degradated through an ubiquitin system by the 26S proteasome. The free unbound 
Nuclear Factor κB (NF-κB) can then translocate to the nucleus and activate the 
transcription of specific target genes 103 .  
 
Pathway 2 “PI3K induced-signalling pathway” 
IL-12 production has been also linked to mitogen-activated protein (MAP) kinases 
pathway. Three subgroups of MAP kinases have been identified: extracellular signaling 
regulated kinases ERKs, c-Jun N-terminal kinase (JNK) and the p38 MAPK 104. After 
stimulation of TLR4 by LPS, phosphoinositide-3 kinases (PI3Ks) pathway is activated 
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leading to a downstream phosphorylation of serine/threonine kinase Akt and extracellular 
signal-regulated protein kinases 1/2 (ERK1/2) 105. Akt activation modulates the activation 
of p38 MAPK and JNK. The production of IL-12 is regulated by PI3K in a negatively 
manner while p38 MAPK and JNK are positively regulated 106. 
 
Pathway 3 “G proteins and cAMP” 
Heterotrimeric G proteins participate in the activation of MAPK and Akt signaling 
pathways. G i/o-mediated activation of the MAPK is independent of the canonical 
signaling cascade. Heterotrimeric G proteins inhibit adenylate cyclase activity and the 
cAMP accumulation in human monocytes. High cAMP levels are able to hamper IL-12 
production. It has been reported that Gαi-protein suppresses IL-12 production via Akt 
signaling (JNK, and ERK 1/2 pathway, but not p38) independently of PI3 kinase (see 
figure 1.3) 107,108.  
 
 
Figure 1.3 LPS-stimulated pathways associated with IL-12 regulation. LPS stimulates the 
TLR4-mediated activation of the NFĸB-pathway and thereby the production of TNF-α, IL-6 and 
IL-12p40. Gαi-mediated inhibition of adenylate cyclase and cAMP accumulation, Gβγ-mediated 
activation of Akt pathway but not p38. Adapted from Hildebrand et al.,109. 
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1.6 Aim 
 
During my Masters thesis we found that IL-12 production was strongly decreased in 
dendritic cells after incubation with D-HG whereas IL-10 production was increased. As 
these two cytokines are important players in the regulation of an anti-tumour response, D-
HG could be involved in the immunosuppression in the tumour environment. 
The aim of this thesis was to further characterize the effects of HG on immune cells and 
tumor cells (differentiation, effects on metabolism) and to evaluate possible mechanisms 
which are involved in the suppression of IL-12 production in dendritic cells (regulation of 
transcription factors and signalling pathways).  
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2. Material  
 
2.1 Equipment 
 
2.1.1 Cell Culture  
Equipment Company 
AMG Microscope Evos xl 
 
Fischer Scientific, Darmstadt Germany 
 
CASY Cell Counter and Analyzer System 
Model TT 
 
Roche Innovatis AG, Reutlingen Germany 
Centrifuge Biofuge fresco  
 
Heraeus, Osterode, Germany 
 
Centrifuge Megafuge 3,0 R  
 
Heraeus, Osterode, Germany  
 
Hemocytometer Marienfeld, Lauda-Königshofen, Germany 
Incubator BBD 6220  
 
Heraeus, Osterode, Germany  
 
Laminar Flow Air HA 2472  
 
Heraeus, Osterode, Germany  
 
pH-Meter  
 
Hanna Instruments, Kehl am Rhein, Germany 
 
Vortex 
 
Scientific Industries, New York, USA 
 
Wellwash™ Microplate Washer 
 
Thermo Electron Corporation, Darmstadt 
Germany 
 
2.1.2 Elutration  
Equipment Company 
Centrifuge Avanti J-20XP; Rotor JE 5.0  
 
Beckmann, München, Germany 
 
Elutriator Avanti J-20XP  
 
Beckmann Coulter, Krefeld, Germany 
 
Waterbath Julabo, Seelstadt, Germany 
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2.1.3 Lysate, Isolation and PCR  
Equipment  Company 
Heat sealer 
 
Eppendorf, Hamburg, Germany 
Multipipette Multipette plus  
 
Eppendorf, Hamburg, Germany  
 
Multipipettor Multipette plus 
 
Eppendorf, Hamburg, Germany 
NanoDrop ND1000  
 
Thermo Fisher Scientific, Schwerte, Germany  
PCR-Thermocycler Modell PTC-200  
 
MJ-Research/Biometra, Göttingen, Germany 
 
Realplex Mastercycler epGradient S  Eppendorf, Hamburg, Germany  
Rotilabo® mini centrifuge 
 
Carl Roth, Karlsruhe, Germany 
Welding machine for PCR plates Fermant 
400 
Josten & Kettenbaum, Bensberg, Germany 
 
 
2.1.4 Western Blot  
Equipment Company 
Electrophoresis Device Biometra,Göttingen, Germany 
 
Forceps 
 
Aesculap, Tuttlingen, Germany 
ImageQuant LAS4000 GE Healthcare, Freiburg, Germany 
 
Pipetboy 
 
Integra Biosciences, Fernwald, Germany 
Power supplies 
 
Biometra, Göttingen, Germany 
Pulsed field electrophoresis 
 
GE Healthcare, Chalfont St Giles, UK 
Pulsed field gel electrophoresis equipment 
 
Biostep, Jahnsdorf, Germany 
Test tube shaker IKA®  Sigma-Aldrich, St. Louis, MO, USA 
Thermomixer  
 
Eppendorf, Hamburg, Germany 
Water purification system  Millipore, Eschborn, Germany 
Western-Blot-camera Biometra, Göttingen, Germany 
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2.1.5 Flow Cytometry  
Equipment Company 
FACS Calibur flow cytometer BD Biosciences, Franklin Lakes, NJ, USA 
 
2.1.6 Respirometry 
Equipment Company 
Gastight 1700 Syringes (10,25,50µl) 
 
Hamilton, Bonaduz, Switzerland 
Hot-Air Disinfectable Gassed Incubator BBD 
6220 
Termo Fisher, Langenselbold, Germany 
OxoDish® 
 
PreSens, Regensburg, Germany  
Oxygraph-2k 
 
Oroborus Instruments, Innsbruck, Austria 
SDR SensorDish® Reader  
 
PreSens, Regensburg, Germany 
  
2.2 Consumables 
 
2.2.1 Cell Culture  
Material Company  
Cell Culture Flask 
 
Costar, Cambridge, USA  
 
Cell culture plates BD, Franklin Lakes, NJ, USA 
Cryo tubes  Corning, Corning, NY, USA 
Microtiter plates (6, 12, 96 wells) Falcon, Heidelberg, Germany  
 
Pipette Tips 
 
Eppendorf, Hamburg, Germany 
Pipettes (2, 5, 10, 25, 50ml) Costar, Cambridge, USA  
 
Plate for ELISA  
 
Costar, Cambridge, USA  
 
Polystyrene test tubes Falcon, Heidelberg, Germany 
Polystyrene test tubes with cell strainer cap Corning, Corning, NY, USA 
Sterile Filter 
 
Millipore, Eschborn, Germany  
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2.2.2 Lysate, Isolation and PCR  
Material Company  
Cell scrapers Sarstedt, Nümbrecht, Germany 
Cell strainer (70µm, 100µm) Falcon, Heidelberg, Germany 
Combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Heat sealing film  Eppendorf, Hamburg, Germany 
Micro test tubes (0.5ml, 1.5ml, 2ml)  Eppendorf, Hamburg, Germany 
Micropore filters Sartorius, Göttingen, Germany 
PCR plate Twin.tec 96 well Eppendorf, Hamburg, Germany 
Syringe Filters, sterile Sartorius, Göttingen, Germany 
Syringes and needles Becton Dickinson, Heidelberg, Germany 
Twin Technology PCR plates (96 wells) Eppendorf, Hamburg, Germany 
 
2.2.3 Western Blot  
Material Company  
Filter paper 3MM Whatman, Dassel, Germany 
 
Fotofilm Hyperfilm
TM 
ECL  Amersham, Braunschweig, Germany 
 
HyperfilmTM ECL GE Healthcare, Chalfont St Giles, UK 
Immobilon-P PVDF membrane Millipore, Schwalbach, Germany 
 
2.3 Reagents  
 
2.3.1 Cell Culture 
Reagent Company 
Bovine serum albumine Sigma-Aldrich, St. Louis, MO, USA 
CasyTON Roche, Basel, Switzerland 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, SHDB7695v, St. Louis, 
MO, USA  
Dulbecco´s Modified Eagle Medium (DMEM) High 
Glucose 
GIBCO, 21969-035 Paisley, UK 
Dulbecco´s Modified Eagle Medium (DMEM) Low 
Glucose 
GIBCO, 31885 023, Paisley, UK 
Fetal Calf Serum, FCS PAA, A11102, Freiburg, Germany 
 
Granulocyte-macrophage colony-stimulating factor, 
GM-CSF 
 
Peprotech, 300 03, Hamburg, Germany 
Interleukin- 4 (IL-4) 
 
Peprotech, 200 04, Hamburg, Germany 
L-Alanyl-L-Glutamine 
 
Biochrom, K0302, Berlin, Germany 
Lipopolysaccharides, LPS ENZO, ALX-581-009, Lörrach, 
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 Germany 
Penicillin/Streptomycin (Pen/Strep) 
 
GIBCO, 15140122, Paisley, UK 
Phosphate Buffered Saline (PBS) 
 
Sigma, D8537, St. Louis, MO, USA 
RPMI Medium 1640 (1X) 
 
GIBCO, Paisley, UK 
Trypsin/EDTA 
 
PAN Biotech, P10 024100, Aidenbach, 
Germany 
 
2.3.2 Elutration  
Reagent Company 
Aqua B.Braun, Melsungen, Germany 
Bovine serum albumine Sigma-Aldrich, St. Louis, MO, USA 
CasyTON Roche, Basel, Switzerland 
H2O2 Merck, Darmstadt, Germany 
Hanks’ Balanced Salt Solution Sigma-Aldrich, St. Louis, MO, USA 
HCl Carl Roth, Karlsruhe, Germany 
Isopropanol Braun, Melsungen, Germany 
PBS Sigma-Aldrich, St. Louis, MO, USA 
 
2.3.3 Lysate, Isolation and PCR  
Reagent Company 
2-Mercaptoethanol Gibco/Life Technologies, Carlsbad, CA, 
USA 
Nuclease-free water Gibco/Life Technologies, Carlsbad, CA, 
USA 
 
2.3.4 Western Blot  
Reagent Company 
Acrylamide Carl Roth, Karlsruhe, Germany 
APS Merck Millipore, Billerica, MA, USA 
TEMED Sigma-Aldrich, St. Louis, MO, USA 
Triton X100 Sigma-Aldrich, St. Louis, MO, USA 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA 
 
2.3.5 Flow Cytometry  
Reagent Company 
FACS clean BD Biosciences, Franklin Lakes, NJ, USA 
FACS flow BD Biosciences, Franklin Lakes, NJ, USA 
FACS rinse BD Biosciences, Franklin Lakes, NJ, USA 
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2.3.6 Respirometry 
Reagent Company 
2-Propanol Braun, Melsungen, Germany 
Methanol Thermo Fisher Scientific, Waltham, MA, USA 
 
2.3.7 Inhibitors and Metabolites 
Inhibitor / Metabolite  Concentration Catalogue # Company 
Cyclosporin A 
(Sandimmune ) 
32pM  Novartis, Basel, 
Switzerland 
D- α -Hydroxyglutaric acid 
disodium salt (D-HG) 
 
10mM H-8378 Sigma-Aldrich, St. Louis, 
MO, USA 
Rotenon 
 
0.1 µM R8875 Sigma-Aldrich, St. Louis, 
MO, USA  
L- α -Hydroxyglutaric acid 
disodium salt (L-HG) 
 
10mM 90790 Sigma-Aldrich, St. Louis, 
MO, USA 
Nicotinic acid  
 
100µM 72309 Sigma-Aldrich, St. Louis, 
MO, USA 
Oligomycin  0.5µM 1404199 Sigma-Aldrich, 
Taufkirchen, Germany 
cAMP 
 
100µM 1337 Tocris, Wiesbaden, 
Germany 
α-Ketoglutarate (Di-Keto) 
 
10mM K-1875 Sigma-Aldrich, St. Louis, 
MO, USA 
Forskolin  10µM 3828S Cell Signaling, Germany  	
2.3.8 Antibodies for Western Blot 
Antibody  Species Dilution Company 
Anti-AKT Polyclonal Rabbit 1:1000 Cell signaling, 9272S 
Anti –IgG Rabbit (HRP-
conjugated) 
Polyclonal Goat 1:2500 Dako, P0448 
Anti-Actin (human) Rabbit (IgG) 1:2000 Sigma, A 2066 
Anti-IgG Goat HRP Polyclonal Rabbit 1:2500 Dako, P0449 
Goat-Anti-Mouse Goat 1:2500 Dako, HRP P0447 
Anti-HIF Rabbit (IgG) 1:1000  Santa Cruz, SC10790 
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Anti-IκB-α Monoclonal 
Mouse 
1:1000 Cell signaling, 4814S 
Anti Oxphos Rodent 1:5000 Abcam, ab110413 
Anti P-p38 
 
Polyclonal Rabbit 1:1.000 Cell signaling, 9211S 
Anti p38 Polyclonal Rabbit 1:1000 Cell signaling, 9212S 
Anti P-Akt Polyclonal Rabbit 1:2000 Cell signaling, 9271S 
Anti Tubulin Monoclonal 
Mouse 
1:5000 MECK, 05-829 
 
2.3.9 Molecular Kits 
 
2.3.9.1 Lysate, Isolation and PCR  
Kits Company 
dNTPs Roche diagnostics, Mannheim, Germany 
QuantiFast SYBR-Green Qiagen, Hilden, Germany 
 
Random-Decamer-Primer Ambion, Darmstadt, Germany 
 
Reverse Transcriptase M-MLV Promega, Mannheim, Germany 
 
RNA Spike-in-Kit Agilent Technologies, Böblingen, Germany 
 
RNAlaterTM Qiagen, Hilden, Germany 
RNase-free DNase Set Qiagen, Hilden, Germany 
RNeasy Midi- and Mini-Kit Qiagen, Hilden, Germany 
 
RNeasy Mini Kit Qiagen, Hilden, Germany 
 
2.3.9.2 Western Blot  
Kits Company 
AmershamTM ECLTM Prime Western Blotting GE Healthcare, Chalfont St. Giles, UK 
ECL-Detection-Kit GE Healthcare, Chalfont St. Giles, UK 
 
ReBlot Plus Mild Milipore, Darmstadt, Germany 
 
SDS Sigma-Aldrich, St. Louis, MO, USA 
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2.3.9.3 ELISA 
Kits Company 
DuoSet ELISA  
 IL-10, IL-12,  
R&D Systems, Wiesbaden, Germany 
Cyclic AMP XP Assay Kit #4339 Cell signaling, Germany  
 
2.3.10 Molecular weight standard proteins 
Western Blot Standard Company 
Kaleidoscope Pre-stained Standard BioRad, München 
 
Spectra Multicolor Broad Range Protein 
Ladder  
Thermo scientific, Lithuania #26634 
Rat heart Mitochondria MitoSciences, Oregon, USA  
Lot. MS812/H2631 
Rat heart Mitochondria  Abcam, Cambridge, UK 
MS812 Lot. L0163 
 
2.3.11 Primers for qRT-PCR 
Genes Primer sequence 
GPR109 Forward 5’ GCG-TTG-GGA-CTG-GAA-GTT-TG 3’ 
 
GPR109 Reverse 5’ GCG-GTT-CAT-AGC-CAA-CAT-GA 3’ 
 
 
2.3.12 Antibodies for Flow cytometry 
Specificity Isotype Fluorochrome Clone Manufacturer 
CD1a Mouse IgG1 PE SFCI19Thy1A8 
 
Beckman Coulter, 
CA, USA 
CD80 Mouse IgG1 APC 2D10 
 
Biolegend, CA, USA 
CD83 Mouse IgG1 PE-Cy7 HB15e 
 
eBioscience, CA, 
USA 
CD86 Mouse IgG1 FITC 2331( FUN-1) 
 
BD, Franklin Lakes, 
NJ, USA 
HLA-DR Mouse IgG2a FITC B8.12.2 
 
Beckman Coulter, 
CA, USA 
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2.4 Cell Lines 
 
U87-MG: Human glioblastoma cell line was kindly provided by Prof. Dr. med. Peter Hau, 
Department of Neurology, University of Regensburg, Regensburg, Germany; source 
(American Type Culture collection). 
 
TP365-MG: Human glioblastoma cell line was provided by Prof. Dr. med. Markus J. 
Riemenschneider, Department of Neuropathology, University of Regensburg, Medical 
School, Regensburg, Germany. 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM371063) 
 
2.5 Software 
 
2.5.1 Software for qRT-PCR 
 
Unmodified, HPLC-purified oligonucleotides were designed using UCSC genome 
browser and PerlPrimer software followed by the analysis under Gene RunnerPrimer. 
Sequences were purchased from Eurofins MWG Operon (Ebersberg, Germany). 
 
 
 
Software Company 
CellQuestPro BD, Heidelberg 
 
GraphPad Prism 6 GraphPad Software, La Jolla, USA 
 
PubMed www.ncbi.nlm.nih.gov/entrez 
 
DatLab4 PreSens, Regensburg 
 
Microsoft Office 2011 Microsoft Redmond, USA 
 
Gene runner version 3.05 http://www.generunner.com 
 
PerlPrimer version 1.1.14 http://perlprimer.sourceforge.net/ 
 
UCSC Genome browser http://www.genome.ucsc.edu 
 
FlowJo v9.5.3 FlowJo,LLC, Ashland, OR, USA 
 
ImageLab v4.0 Bio-Rad, Munich, Germany 
 
Enrichr Amp.pharm.mssm.edu/Enrichr/ 
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3. Methods 
 
3.1 Standard Cell Culture Procedures 
 
3.1.1 Freezing and Thawing 
 
Cell aliquots were quickly thawed and immediately transferred in 10 ml of cell culture 
medium to avoid any toxic effects of dimethyl-sulfoxide (DMSO, Sigma). After 
centrifugation (300xg, 7 minutes) the supernatant was discarded and cells were 
resuspended in fresh medium and plated.  
For cell storage, cells were transferred to RPMI with 40% Fetal Calf Serum (FCS, PAA) 
and 10 % DMSO and frozen in liquid nitrogen. 
3.1.2 Splitting of adherent cells 
 
To split cells, culture medium was removed and cells were washed with Phosphate 
Buffered Saline (PBS, Sigma); Trypsin/EDTA (PAN) was added, and cells were 
incubated for 5 minutes in the incubator and subsequently neutralized with fresh medium. 
The suspension was centrifuged at 300xg for 7 minutes, the supernatant was discarded 
and the pellet was resuspended in fresh medium. The amount of trypsin was adapted to 
the size of the culture flask, for a 162cm2 Corning Flask 3ml of trypsin were used, for a 
75cm2 Corning Flask 1 ml and for a 25cm2 Corning Flask 350µl were used. 
3.2 Cell types and culture conditions  
 
3.2.1 Cancer cell lines U87, TP365 
 
Both cell lines were cultured in DMEM supplemented with 0.5% Pen/Strep, 1% 
glutamine and 10% FCS in a humified atmosphere of 95% air, 10% CO2 at 37°C. The 
splitting of the cells was performed after 3 days, or after 75% of confluence was reached.  
Depending on the experimental setting different cell densities were employed.  
For RNA isolation and protein measurement, 2.5x106 cells were plated in 6-well plates 
with a final volume of 4ml. Every experimental setting was performed in parallel in 
DMEM High glucose (4.5g/L) and Low Glucose (1g/L) plus supplements. 
For respirometry with the Presens technology, densities of 100 000, 200 000, 300 000 
cells per ml were plated in an OxoDish® for 1 hour to achieve adherence, followed by the 
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addition of metabolites and measurement with SDR SensorDish® Reader for 24 hrs. For 
respirometry with the oxygraph technology, 1x106/ml was added into each chamber with 
an end volume of 2ml during 2-3 hours.  
3.2.2 Immune Cells  
 
3.2.2.1 Monocyte isolation  
 
Peripheral blood mononuclear cells (PB-MNCs) were separated by leukapheresis of 
healthy donors, followed by density gradient centrifugation over Ficol/Hypaque. 
Monocytes were then isolated by counter current centrifugal elutriation as described 
previously 110.  
Elutriation was performed in a J6M-E centrifuge equipped with a JE 5.0 elutriation rotor 
and a 50ml flow chamber (Beckman, Munich, Germany). The chamber was sterilized 
with 6% H2O2 for 20 min and washed with PBS. Afterwards the calibration was 
performed at 2500 rpm and 4°C with Hanks Buffer. Mononuclear cells (MNCs) were 
loaded into the chamber and fractions were collected. Monocytes are the largest cells 
within MNCs hence are mainly obtained in the last fraction. The purity of monocytes was 
at least 85% as determined by the expression of CD14, a monocyte-specific antigen.  
 
                        Table 3.1: Elutriation parameter and cell types 
Fraction Volume (ml) Main cells isolated 
Ia 1000 Platelets  
Ib 1000 B- and T- lymphocytes. NK cells 
IIa 1000 
IIb 500 
IIc 400 
IId 400 
III 800 Monocytes  
 
3.2.2.2 Generation of dendritic cells 
 
For the generation of dendritic cells, isolated monocytes were cultured in culture flasks at 
a concentration of 1x106 cells/ 1.5ml for 7 days in RPMI 1640. The medium was 
supplemented with 10% FCS, 2mM glutamine, 50U/ml of penicillin and 
50 mg/ml of streptomycin (0.5%), 225U/ml granulocyte macrophage colony 
stimulating factor (GMCSF, Peprotech) and recombinant IL-4 (144 U/ml, Peprotech) 111. 
After 7 days the cells were harvested, immature dendritic cells (iDCs) were seeded at 
different densities depending on the experimental test.  
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• For supernatant experiments 200 000 iDCs were plated per well in a 24-well plate 
with 1ml of supplemented RPMI 1640. DC maturation was induced by addition of 
100ng/ml lipopolysaccharide (LPS). For some samples the metabolites D-HG (D- 
α- Hydroxyglutaric acid disodium salt) and L-HG (L- α- Hydroxyglutaric acid 
disodium salt) were added during the culture. Supernatants were harvested after 
24h, frozen at -20°C and used for cytokines determination. 
• For experimental settings such as RNA isolation, Protein isolation or HG uptake 
measurements, 2.5x106 iDCs/well were seeded in a 6-well plate. In a final volume 
of 4ml, which include RPMI + supplement, 100ng/ml LPS and metabolites.  
• For experimental settings, such as determination of mitochondrial respiration, 
cells were plated (in 24-well OxoDish® for PreSens technology) or added (per 
chamber for Oxygraph technology) at a 1x106 cells/ml concentration, plus LPS 
and metabolites addition.  
 
3.3 Measurement of cytokines and Lactate 
 
3.3.1 Enzyme Linked Immunosorbent Assay (ELISA) 
 
Interleukins were determined in the culture supernatants using commercially available 
enzyme-linked immunosorbent assay (ELISA) kits (Duoset ELISA, R&D Systems, 
Minneapolis, MN) according to manufacturer’s protocols.  
96 well plates were coated with 10µL/well capture antibody for each cytokine. Plates 
were incubated at room temperature (RT) overnight. The next day, plates were washed 
three times with 400µL of Elisa wash buffer (0.05% Tween in PBS) per well. Plates were 
blocked for 1 hour by adding 300µL/well Reagent Diluent (1% BSA in PBS). Meanwhile 
samples were thawed at RT; a seven point standard was prepared according to 
manufacturer’s recommendation. Plates were washed three times to eliminate excess of 
blocking solution. Prepared standards and the samples were pipetted, 100µL per well. 
Samples were incubated for 2 hours at RT. Plates were washed three times, the detection 
antibody was added, and incubated for 2 hours at RT. Plates were aspirated/washed, the 
working dilution of 100µL/well Streptavidin-HRP was added, and incubated at RT 
avoiding light exposure for 20 minutes. Plates were washed; 100uL of substrate solution 
(equal volume of hydrogen peroxide and tetramehtylbenzidine) was added to plate wells 
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for 20 minutes, stored at RT in the dark. Without washing, 50µL of stop solution was 
added. Plates were tapped gently to ensure thorough mixing. The optical density of each 
well was immediately determined with a microplate reader which was set according to the 
interleukin recommended wavelength.  
To measure cAMP levels on iDCs, 1x106 cells were placed on FACS tubes, centrifuge at 
1400rpm during 7min and the supernatant discarded. Cells were then resuspended with 
1mL cold PBS, and this procedure was repeated 2 times. Cells were then Lysated adding 
200µl 1x lysisbuffer (diluted in H2O, stored in -20°C), incubated on ice for 10 mins, 
centrifuged at 1600rpm during 4 min, followed by the supernatant collection and storage 
at -80°C.  Supernatant was then use to performed cAMP XP Assay according to 
manufacter protocol. 
3.3.2 Enzymatic determination of lactate  
 
 To determine lactate concentrations, supernatants were harvested and frozen at -20°C 
until analysis. Lactate concentration was determined enzymatically using an ADVIA 
1650 instrument (Bayer, Tarrytown, NY) and specific reagents (Roche, Mannheim, 
Germany). All values were corrected for lactate concentration of the culture medium. 
Lactate measurement was performed at the Department of Clinical Chemistry (University 
Hospital Regensburg, Germany). 
3.4 Cell counting with a cell analyzer (CASY system) 
 
The cell number was determined by using a cell analyzer, the CASY system. An aliquot 
of 50µl from the cell suspension was taken and placed in 10ml of Casy-ton solution. The 
mean of three cycles, (400µl each) was calculated by the Casy® software. In addition to 
cell number, cell diameter and volume were determined. Appropriate cursor settings 
based on cell size for determining cell number and viability were established for each cell 
type. 
 
3.5 RNA /Protein lysates 
 
3.5.1 RNA 
 
After trypsinazing and counting the cells, the samples were centrifuged at 300xg for 7 
minutes. Supernatant was discarded, and the pellet was resuspended in 350µl Lysis Buffer 
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(10µl of ß-mercaptoethanol per 1ml of Lysis Buffer (Qiagen,Germany) ) and stored at -
80ºC.  
3.5.1.1 RNA Sequenciation 
RNA was isolated using the Qiagen RNeasy kit. RNA-seq libraries were generated using 
the ScriptSeqTM Complete Kit from Illumina according to the manufacturer’s instructions 
(Experimental setting performed by Prof.Dr. Michael Rehli’s research group). Libraries 
were sequenced paired-end (2 x 75bp) on a HiSeq 3000 at the Biomedical Sequencing 
Facility (BSF) in Vienna, Austria. 
3.5.2 Protein 
 
3.5.2.1 Ripa Buffer 
 
After trypsinaizing and cell counting, cells were centrifuged at 300xg for 7 minutes, 
supernatant was discarded and pellet washed 2 times with PBS, after the second wash the 
pellet was resuspended with 100µl (per 5x106 of cells) of Ripa Buffer. Aadherent cells 
were detached with cell scrapers and thereafter vortexed thoroughly for 1 minute, frozen 
for 5 minutes at -20ºC, vortexed again and placed in liquid nitrogen followed by the final 
storage at -80ºC.  
3.5.2.2 Phosphorylate Buffer 
 
For subsequent analyzes of the phosphorylated form of proteins, cells were lysed after 
different incubation times (30 minutes, 1hr or 24hrs). After incubation times, well plates 
were placed on ice and the supernatant was transferred into 15ml centrifuge tube and 
centrifuged. Subsequently, both the cells adherent in the culture plate and the centrifuged 
cells were washed twice with ice-cold PBS, the centrifuged cells were then transferred 
into 1.5ml tube. In the next step, the cells in the 1.5ml tube were resuspended in 500µl of 
Buffer B and recentrifuged again. During the centrifugation time, the adherent cells were 
also treated with 500µl of Buffer B. Cells treated with Buffer B, which mainly contains 
protease and phosphatase inhibitors, was used to prepare the cells for subsequent lysis 
with Buffer C. After Buffer B had been removed from both cell populations, 150µl of 
Buffer C was pipetted onto the adherent cells. Then adherent cells were detached with cell 
scrapers, combined with the centrifuged cell fraction and placed on ice for 10 minutes. 
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Then 150µl of sodium dodecyl sulfate (sodium dodecyl sulfate, SDS) sample buffer (2x) 
was added, following heated at 95°C for 10 minutes and stored at -80°C until further use. 
Buffer A 
10mM      (1ml)   Tris/HCl (pH 7.9) (1M) 
60mM      (447mg)   KCl 
1mM      (37mg)   EDTA 
100ml                H2O 
  
Buffer B 
 
1.5mM (3µl) EDTA (pH 8.0) (500mM) 
1mM (10µl) Dithiotreitol (100mM) 
1mM (5µl) EGTA (200mM) 
50mM (50µl) β-Glycerophosphat (1M) 
50mM (50µl) Sodium Flouride (1M) 
25mM (100µl) Sodium Pyrophosphat (250mM) 
1mM (5µl) Sodium Orthovanadate (200mM) 
2µg/ml (2µl) Leupeptin (1mg/ml) (Roche, Mannheim) 
2µg/ml (2µl) Pepstatin A (1mg/ml) (Roche, Mannheim) 
2µg/ml (1µl) Aprotinine (2mg/ml) (Roche, Mannheim) 
1ml  Buffer A 
 
Buffer C (Lysate buffer)  
 
0.4% (40µl) Nonidet P40 (10%) (Boehringer, Ingelheim) 
100µg/ml (5µl) Chymostatin (20mg/ml) (Roche, Mannheim) 
10µg/ml (2µl) Bestatin (5mg/ml) (Roche, Mannheim) 
3µg/ml (1µl) E64 (3mg/ml) (Roche, Mannheim) 
1mM (1µl) 1,10-Phenantrolin (0.1mg/ml) 
1ml  Buffer B 
 
SDS (2x) Buffer  
 
20% (10ml) Glycerin 
125mM (5ml) Tris/HCl (pH 6.8) (1.25 M) 
4% (2g) SDS 
10% (5ml) 2-Mercaptoethnol 
0.02% (10mg) Bromophenol Blue 
50ml  H2O 
 
3.6 Western Blot Analysis 
 
3.6. 1 Preparation of Sodium Dodecyl Sulfate (SDS) Gel  
 
Protein samples were separated using a discontinuous gel system, which is composed of 
stacking and separating gel layers that differ in salt and acrylamide (AA) concentration. 
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3.6.1.1 Material 
 
SDS-PAGE stock solutions 
• 70% Isopropanol 
• 12% separating gel,  
• Stock solution (Tris/HCL; SDS; Acrylamid) 
• Tetramethyllethylenediamine (TEMED) 
• 10% ammonium persulfate (APS) 
• 5% Stacking gel (Tris/HCL; SDS; Acrylamid) 
• Running Buffer: 5X Laemmli-Electrode Buffer. 
• Distillate Water 
• 2x SDS- Sample Buffer 
• Protein Sample 
• Standard: Kaleidoscope Prestained Standard (BioRad) 
3.6.1.2 Required buffers and solutions: 
 
• Separating gel buffer: 90.83g (1.5M) Tris/HCl, pH 8.8, in 1L ddH2O 
• Stacking gel buffer: 30g (0.5M) Tris/HCl, pH 8.8, in 1L ddH2O 
• SDS: 10g (10%) SDS, in 1L ddH2O 
• Ammonium persulfate: 10g APS, in 1L ddH2O  
• Running Buffer (5X): 15g (40mM) Tris, 21g (0.95M) Glycine, 15g (0.5%) SDS 
• Running Buffer (10X) for Oxphos: Tris- Base 30g, Glycin 144g, SDS 10g and 1L 
distilled water. 
• Running Buffer (1X) for Oxphos: 10X Running Buffer for Oxphos 100ml, ddH2O 
900ml.  
 
The separating gel was prepared a day prior to the electrophoresis and overlaid with 
isopropanol; 15 minutes of incubation at room temperature were necessary to finalize 
polymerization. Isopropanol was exchanged by the stacking gel, and the comb was 
inserted. After polymerization, the gel was stored overnight at 4°C.  
The following day, gel was mounted in the electrophoresis tank, previously filled with 1x 
running buffer. For the majority of the antibodies, with the exception of samples analyzed 
for OXPHOS antibody, protein samples were loaded and the gel ran with 80 volts (V) 
until the bands reached the surface of the stacking gel (20min). Next, the voltage was 
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increased to 100V, after 15 minutes the voltage was increased to 120V and the gel ran for 
2hrs.  
For samples where mitochondrial proteins were analyzed, 5µl of sample and marker were 
loaded in a 10% gel, the gel initially ran in 1X Running Buffer for Oxphos with 90V 
during 30 min, and afterwards the voltage was increased to 120V for 1.5hrs.  
 
Depending on the size of the desired proteins the gel concentration can vary:  
Protein size Separating Gel 
< 30 kDa 14% 
25 – 70 kDa 12 % 
> 70 kDa 10% 
 
For the presented experiments, with the exception of the experiment set up for samples 
where mitochondrial proteins were analyzed, a 12% separating gel was used. 
3.6.2 Western Blot  
 
3.6.2.1 Required Solutions and Material: 
 
• 70 % Isopropanol  
• Anode- Buffer A: 36.3g (0.3M) Tris, pH 10.4, 20% Methanol, in 1L dd H2O 
• Anode-Buffer B: 3.03g (25mM) Tris, pH 10.4, 20% Methanol, in 1L dd H2O 
• Cathode-Buffer C: 5.2g (4mM) ε -amino-n-caproic acid, pH 7.6, 20% Methanol, 
in 1L dd H2O 
• Blot Buffer 10X for Oxphos: 30.28g Tris-Base, 144g Glycin in 1L Distilled 
Water. 
• Blot Buffer 1X for Oxphos: 100ml Blot Buffer 10X for Oxphos, 700ml Distilled 
Water, 200ml Methanol 100% 
• PVDF-Membran (Millipore) 
 
• Paper Filter (Whatman) 
 
After separation by SDS-PAGE, with the exception of samples analyzed for 
mitochondrial proteins, proteins were electro-blotted into a PVDF membrane 
(Immobilon-P, Millipore) using a three-buffer semi-dry system and visualized by 
immunostaining using specific antibodies and ECL detection kit. 
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Three Whatman 3MM filter papers soaked with buffer A were placed on the anode, and 
three Whatman 3MM filter papers soaked with buffer B, followed by the membrane, 
previously cut smaller than the gel size and soaked first with isopropanol and after 2 
minutes with buffer B.  
The gel was placed on top of the membrane. Three Whatman 3MM filter papers soaked 
with buffer C were placed on top of the gel followed by the cathode. Air bubbles in-
between the layers had to be avoided. Protein transfer was conducted for 1hr at 11V. 
In case of the samples analyzed for mitochondrial proteins, 4 whatman filter papers, one 
membrane and the gel were placed in a bowl with 1X blot buffer for Oxphos. Following 
to this, 2 filter papers were separated and placed in the chamber blot, followed by the 
membrane placing, and then with the help of a spatula the gel was positioned on the top of 
the membrane, being careful not to leave bubbles in between the gel and the membrane, 
next the gel was covered with the other 2 soaked filter papers, and homogeneously 
pressed against it with a 5ml pipette, in order to eliminate the exceeding buffer. Protein 
transfer was conducted for 1.5hrs at 15V.  
3.6.3 Immunodetection  
 
3.6.3.1 Required buffers and materials: 
 
• 10x Tris buffered saline (TBS) 
• Distilled water 
• TWEEN 20 
• Milk powder/BSA 
• Primary antibody 
• Secondary antibody/HRP-conjugated 
• ECL Solution 
• 30% Hydrogen Peroxide 
• ReBlot- Stripping- Solution 
• Wash buffer: 1x TBS with 0.1% TWEEN 20 
• Wash Buffer for Oxphos 10X: 20mM Tris (24.2g), 150mM NaCl (80g), <1000ml 
(ca.970ml) pH=7.6 
• Wash Buffer 1X TBS-T for Oxphos: 10X Wash Buffer for OXPHOS 100ml, 
distilledwater 900ml, Tween 20 1ml.  
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• Blocking buffer: Wash Buffer with 5% Milk 
• Blocking buffer for OXPHOS: BSA 5% 
 
With the exception of the samples used to analyze mitochondrial proteins, the blotted 
membrane was blocked with 5% milk powder in PBST overnight at 4ºC according to the 
antibody specifications. 
Next, the membrane was incubated with the first antibody at RT for 1hr (concentration 
according to the antibody).  
After 3 washing steps were performed, each one for 10min with the appropriate washing 
buffer, the membrane was incubated for 1hr at RT with a horseradish-peroxidase (HRP)-
coupled secondary antibody, detecting the isotype of the first antibody.  
Three washing steps were followed by 2 minutes of incubation with ECL solution. Blots 
were exposed to an autoradiography film (HyperfilmTM ECL, Amersham) for 10 seconds 
to 20min depending on the signal intensity. 
The immunodetection procedure for samples analyzed for mitochondrial proteins differs 
from the standard WB procedure. 
After the membrane was cleaned from the Ponceau staining, it was placed in a 50ml 
falcon tube with 5ml 5% BSA to get blocked, during 1h in a horizontal shaker. After the 
incubation time the membrane was incubated overnight with the first antibody OXPHOS 
anti-Mouse (1:5000 dilution = 2µl in 10ml), in the shaker.  
After 1st Ab incubation time, 3 washing steps were performed (5ml at 5, 10, 15min), then 
the membrane was incubated for 1hr at RT with Goat anti-mouse Secondary Ab. Three 
washing steps were followed by 2 minutes of incubation with ECL Solution. 
Chemiluminescence imaging was performed on ImageQuant LAS400 GE HealthCare 
equipment.  
Western Blot procedure for the antibody ERK was performed by Dr. med. Sven Lang in 
the department of “Klinik und Poliklinik für Chirurgie” institute, in the University 
Hospital Regensburg. 
3.6.4 Loading control 
 
3.6.4.1 General protocol for loading control 
 
After developing the membrane two washing steps were performed followed by 15 
minutes of incubation with ReBlot Solution, ending the incubation time, the membrane 
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was washed 3 times, and blocked for 1hr, proceeding with an overnight incubation of 
loading control antibody. The following day, the blot was incubated with the secondary 
antibody. Protein detection was determined after incubation with ECL solution and 
autoradiography. 
3.6.4.2 Ponceau Staining  
 
After the protein transfer, the membrane was placed in a box with 10ml Red Ponceau and 
left for 5 minutes in the shaker. After 5 minutes, the membrane was submerged one time 
in 1X Washing buffer for mitochondrial proteins and placed in a plastic folder and 
posteriorly scanned. After the scanning, the membrane was washed for 5 minutes with 1X 
Washing Buffer for mitochondrial proteins, until the membrane get free of Ponceau.  
 
3.7 RNA Isolation and determination  
 
3.7.1 Preparation of RNA lysate 
 
After trypsinaization and counting the cells, the samples were centrifuged at 300xg for 7 
minutes, the supernatant was eliminated, the pellet was resuspended in 350µl lysis buffer 
(10µl of ß-mercaptoethanol per 1ml of lysis buffer (Qiagen, Germany)) and stored at -
80ºC.  
 
For RNA extraction, 350µl of 70% ethanol was added to the homogenized lysate and 
mixed by pipetting; 700µl of the sample was poured into a Spin Column with 2ml 
collection tube (Qiagen Kit). The sample was centrifuged for 15 seconds at 6708xg and 
the flow-through discarded, followed by the addition of 350µl wash buffer to the column, 
posteriorly the column was centrifuged and the flow through was discarded.  
 
DNAse (10µl) and RNase Free DNase buffer (70µl) was added into the column and 
incubated at room temperature for 15 minutes. Another wash step was performed and the 
flow-through was discarded.  
The next step was the addition of 500µl concentrated wash buffer, followed by a 
centrifugation step, and flow was discarded. Posteriorly 500µl of 80% ethanol were added 
into the column and centrifuged for 2 minutes at 6708xg in order to dry the silica-gel 
membrane; the flow-through and collection tube were removed. Another centrifugation 
step was performed.  
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For elution of the RNA present in the membrane of the column, 30µl of RNase-free H2O 
were pipetted, followed by 1 min of centrifugation at 6708xg.  
The isolated RNA was quantified with a photometer Nanodrop and stored at -80ºC.  
3.8 Real-Time quantitative PCR (RT-qPCR) 
 
3.8.1 Reverse Transcription PCR (RT-qPCR) 
 
Total RNA was reverse transcribed into complementary DNA (cDNA) using Moloney 
murine leukemia virus reverse transcriptase (M-MLV RT) enzyme. Random decamers 
were used to prime cDNA synthesis. The volume of 1µg of total RNA was adjusted to 
13µl with nuclease-free ddH2O and mixed with 1µl Random Decamers (Promega) and 
1µl dNTPs (10mM) on ice. Secondary structures of RNA were dissolved by 5min 
incubation in Thermocycler at 65°C followed by immediate incubation on ice for 1 min. 
After mixing with 4µl M-MLV Buffer (5x;Promega), samples were incubated at 42°C for 
2min. Reverse transcription started upon addition of 1µl RT enzyme (50min, 42°C) and 
was stopped by heat inactivation of the enzyme (15min, 70°C).  
The RNA solution was placed In the PCR-Thermocycler for another 2 minutes at 42ºC; at 
the end of the 2 minutes incubation 1µl of Reverse Transcriptase was added and ran the 
following program. 
 
Temperature Time  
65ºC 5 min Denaturalization 
42ºC 2 min Incubation 
42ºC 50 min  
70ºC 15 min Inactivation of MMLV RT 
10ºC For ever  
Data shown the PCR program used for the transcription of RNA into cDNA. The 
temperatures and duration per cycle are mentioned.  
 
The cDNA was stored at -20ºC. 
3.8.2 Quantitative Real-Time PCR (qPCR) 
 
Reverse transcribed cDNA products were analyzed on a Mastercycler Ep Realplex using 
the QuantiFast SYBR Green PCR Kit. Primer sequences were purchased from Eurofins 
MWG Operon, Ebersberg, Germany except when other companies are mentioned. 18S 
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rRNA was used as a reference gene for all genes of interest. PCR reaction was carried out 
in a 96 well plate format adapted to the Eppendorf Realplex Mastercycler EpGradient S 
system. The amount of amplified DNA relative to reference gene 18S rRNA was 
measured through the emission of light by SYBR green dye after each extension step. 
Melting curve was monitored to determine the specificity of amplification product. 
The reaction component and cycling protocol for RT-qPCR are listed below: 
 
Table 3.2: RT-qPCR reaction composition 
Components Concentration Volume 
SYBR Green mix (2x)  5 µL 
Nuclease-free ddH2O  3 µL 
Template DNA 1000 ng 1 µL 
Primer_sense 10 µM 0.5 µL 
Primer_antisense 10 µM 0.5 µL 
Final Volume  10 µL 
 
Table 3.3: Cycling protocol for RT-qPCR 
Cycle step Temperature Time consumed Number of cycles 
Initial denaturation 95°C 5  min 1x 
Denaturation 95°C 8  sec 45x 
Anneling and Extension 58°C 20 sec 
Final denaturation 95°C 15 sec 1x 
Final extension 60°C 15 sec 
Melting Curve 60-95°C 10 min 1x 
Cooling 4°C Hold  
 
3.9 Respirometry  
 
Mitochondrial respiratory activity was determined under cell culture conditions using the 
PRESENS technology (PreSens Precision Sensing GmbH, Regensburg, Germany) and in 
detail by high-resolution respirometry using the oxygraph O2-k (Oroboros Instruments, 
Innsbruck, Austria). For both applications 1x106 cells/ml were analyzed. The SDR 
SensorDish® Reader is a 24-channel oxygen and pH meter. The optical oxygen 
(OxoDish®) sensor is integrated at the bottom of each well of a 24-well multidish. The 
sensors are luminescent dyes embedded in an analyte-sensitive polymer. The sensors are 
read out non-invasively through the bottom of the multidish by the SensorDish® Reader 
and cells do not have 
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converted automatically to the respective parameter using calibration parameters stored in 
the software.  
For high-resolution respirometry cells centrifuged and resuspended in fresh respective 
culture medium and respiration of suspended cells was measured at 37 °C with chamber 
volumes set at 2ml. Data acquisition and analysis was performed with the DatLab4 
software (OROBOROS, Innsbruck, Austria) including calculation of the time derivative 
of oxygen concentration, signal deconvolution dependent on the response time of the 
oxygen sensor, and correction for instrumental background oxygen flux112. Data points 
were recorded at 1s time intervals. Before closing the oxygraph chamber, 50µl samples 
were taken for determining cell number in each chamber. ROUTINE respiration was 
measured in the first 20min, afterwards D-HG or medium was added. When determining 
the effect of D-HG on dendritic cells LPS was added after 10min of D-HG incubation. 
ROUTINE respiration was measured for one hour, LEAK respiration was determined 
after addition of oligomycin (2µg/106 cells), capacity of complex I to IV (ETS) after a 
stepwise titration of FCCP (final concentration of approximately 3µM, 1µM by step), 
residual oxygen consumption (ROX) not related to the respiratory system was measured 
after addition of rotenone (0,5µM) and myxothiazol (2,5µM). All respiratory parameters 
were corrected for (ROX), mitochondrial oxygen consumption related to ATP production 
was calculated as the difference between ROUTINE and LEAK respiration. In the case of 
the glioma cell lines, respiration could not be normalized to cell number as the cells 
formed clusters, therefore, respective respiratory control ratios were calculated.  
 
3.10 Fluorescence Activated Cell Sorting 
 
Fluorescence activated cell sorting (FACS) is a flow cytometry based method that detect 
both intra- and extracellular protein of interest in/on the cells. Different proteins on the 
same cell can be marked with antibodies conjugated to different fluorochromes.  
Single cells suspended in a medium are injected into a stable stream that forces cells to 
travel one by one in a laminar flow fashion. Cells pass through the beam of laser light. 
Scattered light and fluorescence emission provide information about the particle’s 
properties. Light scattered in forward direction provides information about size of cells 
and side scatter measures granularity of cells.  
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Based on the excitation and emission wavelength of fluorochrome conjugated to cells, 
varying protein expression by cells can be measured. Also, using this fluorochrome 
labelled antibodies; different populations of cells can be sorted and collected.  
 
3.10.1 Extracellular Staining  
 
To access the protein expression, monocyte derived DCs were plated under 3 settings, 1st 
D-HG was added at day 0, 2th D-HG was added at day 5 and 3th D-HG was added at day 
7, followed by the collection of the cells two washing steps with 1 ml FACS buffer were 
performed. Cells under the 3 different culture settings were then stained with surface 
markers: CD1a, CD80, CD83, CD86 and HLA-DR along with the respective isotype 
control. Cells were incubated at 4 oC for 30 minutes. Cells were washed thrice with FACS 
buffer and resuspended in 300µL FACS buffer. Flow cytometric measurement was 
performed on a BD FACS Calibur.  
3.10.2 Intracellular staining.  
 
Monocytes obtained from volunteer blood donors via elutriation were cultured in RPMI 
medium supplemented with IL-4, GM-CSF in T25 flasks. After 7 days of culture cells 
were treated with LPS (100ng/ml), D-HG 10mM and Protein Transport Inhibitor 
(containing Monensin) for 16hrs. After incubation time, monocytes-derived iDCs and 
supernatants were recollected. 1.5x106 cells were placed in FACS tubes and centrifuge 4 
minutes at 1600 RPM, resuspended with PBS, washed and permeabialized with BD 
perm/wash solution 2 times, follow by staining with P40 FITC, P35 APC and IgG 2b 
FITC, IgG1 APC isotypes. Cells were fixed with 4% PFA, and analyzed on FACS 
Calibur.  
Composition of: 
• FACS buffer: 5ml of 60mg/ml Immunoglobulin + 5ml of 10% sodium azide + 
500ml PBS 
• Fixation/Permeabilization solution: 1 part of Fix/Perm concentrate + 3 part of 
Fix/Perm diluent. (BD #554714) 
• Permeabilization buffer: 1 part of 10X buffer + 9 parts of distilled water (BD 
#558050). 
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4. Results 
 
Isocitrate Dehydrogenase (IDH) is an important enzyme that catalyzes the conversion of 
isocitrate to α-ketoglutarate (α-KG). Point mutations in IDH 1 and 2 are frequently found 
in neoplasia including acute myeloid leukemia and glioma. Mutated IDH gains the ability 
to convert α-KG into 2-hydroxyglutarate (HG). HG is referred in the course of this thesis 
as the general structure that includes both enantiomers, D-2-hydroxyglutarate, abbreviated 
as D-HG and L-2- hydroxyglutarate abbreviated as L-HG. IDH mutations suppress 
hematopoietic differentiation in leukemia models 113. However, it is still unclear whether 
HG affects the activation and differentiation of non-malignant hematopoietic cells and its 
impact on immune cell function.   
4.1 Impact of HG on Dendritic Cells 
 
4.1.1 Effect of HG on cytokines production. 
 
Based on the findings that HG affects proliferation and differentiation of tumor cells 
(AML and Glioma cells) we hypothesized that HG also has effects on non-tumoral 
hematopoetic cells. Dendritic cells (DCs) are the most important antigen presenting cells 
(APC) of the immune system, acting as a link between innate and adaptive immune 
response. In response to stimulation, DCs undergo maturation and produce IL-12. IL-12 
production induces the differentiation of naive CD4+ T cells into T helper cells 
(predominantly Th1 helper cells). DCs are also capable to produce immunosuppressive 
cytokines like IL-10, which induces the differentiation of naive CD4+ T cells into Th2 
helper cells.  
During my master thesis I was able to show a suppressive effect of HG on IL-12 
production of DCs. To gain further insight we analyzed the expression of the two IL-12 
subunits p35 and p40 by flow cytometry. DCs were generated from monocytes isolated 
from the blood of healthy donors and cultured in RPMI medium supplemented with IL-4 
and GM-CSF for seven days. This protocol was used throughout the whole study. After 7 
days of culture IL-12 secretion was measured in supernatants of DCs treated either with 
LPS (100ng/ml) alone or in combination with 10mM D-HG and a protein transport 
inhibitor (monensin) for 16hrs. After the incubation time DCs were stained for the 
expression of IL-12 subunits. 
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Figure 4.1. Effects of D-HG on IL-12 subunits. Human iDCs were differentiated from 
monocytes during 7 days and then stimulated either with 100ng/ml LPS alone or in combination 
with 10mM D-HG for 16hrs. A protein transport inhibitor was added (monensin) during 
stimulation. Cells were fixed with 4% of PFA per each 1 million cell and analyzed by flow 
cytometry. A) Representative staining of IL-12 subunits. B) Summarized data of the D-HG effect 
on IL-12 subunits p35 and p40. 3 independent experiments are presented. Statistical analysis was 
tested with Mann-Whitney U test (* p≤0.05, ns not significant). 
 
D-HG did not affect the expression of the p35 subunit of IL-12 (Figure 4.1A; 85.6% 
positive cells after addition of LPS, 85.78% of positive cells when treated with D-HG and 
LPS); whereas p40 subunit expression was clearly reduced in the presence of 10mM D-
HG (19.24% positive cells without D-HG and 10.49% positive cells with D-HG). This 
observation was statistically confirmed by analyzing at least three different donors 
(Figure 4.1B). These results demonstrate that D-HG mediated IL-12 reduction observed 
during previous studies is directly related with the specific suppression of the p40 subunit 
expression.  
Next we investigated whether the suppression of IL-12 secretion is solely induced by the 
oncometabolite D-HG or also by its enantiomer L-HG. This was done by measuring IL-12 
levels as well as IL-10 levels in the supernatant of D-HG and/or L-HG treated DCs.  
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Figure 4.2 Impact of D-HG and L-HG on IL-12 and IL-10 secretion of dendritic cells. 
0.2x106 monocyte-derived DCs were plated in 24 well plates, iDCs were activated with 100ng/ml 
LPS, and in parallel exposed to 10mM of D-HG/L-HG for 24hrs. Supernatants were collected and 
measured for IL-12 and IL-10. The measurement was performed by commercially available 
ELISA. Data represent the mean +/- standard error (SEM) of 14 independent experiments (IL-12) 
and 10 independent experiments (IL-10). Statistical analysis was tested using the Friedman test, 
and Dunn multiple comparison test (** p≤0.01).  
 
The data clearly show that L-HG suppresses the secretion of IL-12 as efficient as D-HG, 
strongly indicating a general suppressive activity of HG (Figure 4.2). Although not 
significant, it was interesting to observe the trend of upregelation of IL-10 under the 
influence of both isoform of HG pointing towards immunoregulatory impact of HG at 
least in human DCs (Figure 4.2). In the following analyses we mainly used D-2-
hydroxyglutarate, abbreviated as D-HG, unless indicated otherwise.  
 
4.1.2 Uptake of D-HG by Dendritic Cells. 
 
In order to gain further insight, how D-HG affects dendritic cells, we measured cellular 
uptake of D-HG. Immature dendritic cells (iDCs) were stimulated with 100ng/ml LPS and 
treated with D-HG at a concentration of 10mM for 24hrs. Following stimulation, 
intracellular levels of D-HG were analyzed by mass spectrometry (analyses performed by 
Dr. Katja Dettmer-Wilde and Prof.Peter Oefner, Institute of Functional Genomics, 
Regensburg). 
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Figure 4.3. Uptake of D-HG by DCs. Human iDCs were differentiated from elutration-separated 
monocytes and were stimulated with 100ng/ml LPS in the presence or absence of 10mM D-HG 
for 24hrs. Cells were washed with PBS and intracellular levels of D-HG were analyzed by mass 
spectrometry (analyses performed by the Institute of Functional Genomics, Regensburg). Data 
represent the mean +/- SEM of 3 independent experiments. Statistical analysis was tested with the 
Wilcoxon-Test ** p≤0.01, ns not significant).  
 
The measurements showed the presence of endogenous D-HG in DCs and that the 
addition of 10mM D-HG showed a 100 fold increase in intracellular levels (Figure 4.3). 
This result demonstrated the capacity of DCs to take up D-HG.  
 
4.1.3 The role of D-HG in TLR signaling pathway 
 
Due to IL-12 production being affected by D-HG we decided to investigate LPS/TLR4 
signaling, a pathway associated with IL-12 production and modulation.  
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Figure 4.4 Schematical representation of TLR signaling pathways and their relation with 
IL-12 production by DCs. A) LPS/TLR4 pathway associated with IL-12 modulation (Modified 
from Hildebrand et al. 2012)114. B) Experimental set-up to evaluate the HG effect on LPS/TLR4 
signaling pathway of DCs.  
 
We performed western blot analyses of monocyte-derived iDCs, seeded in 6 well plates 
(2.5x106 cells in 4 ml medium) and stimulated with LPS or LPS plus D-HG. NF-κB, P-
Akt, P-p38, ERK or HIF protein expression was analyzed in protein lysates by western 
blot analyses. 
 
4.1.3.1 IκB Expression in Dendritic Cells 
 
IκB-α is a regulatory protein that binds NF-κB and traps it in the cytoplasm, inhibiting 
NF-κB activity. IκB activity is controlled by sequential serine-phosphorylation, 
ubiquitination and degradation. It is well known that LPS reduces the expression of IκB, 
thereby promoting NF-κB activity but until now the effect of HG on the NF- κB 
pathway has not been studied. 
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Figure 4.5. NF-κB stimulates IL-12 production in DCs. TLR4 recognizes bacterial LPS and 
utilizes 4 adaptors (which include MyD88) to activate the NF-κB pathway, which is strongly 
related with cytokine production (IL-12, TNF and IL-6).  
Figure 4.6. Expression of IκB protein in DCs. iDCs were stimulated with LPS (100ng/ml) and 
treated with or without 10mM D-HG. After 1 hr of treatment cell pellets were lysed and analyzed 
by Western Blotting. A) Original blots of IκB expression of 3 independent experiments. B) 
Quantification of IκB expression in DCs treated with LPS alone or combined with D-HG. Data 
represent the mean +/- SEM of 6 independent experiments. Statistical analysis was tested with the 
Kruskal-Wallis Test (*p≤0.05, ** p≤0.01, ns not significant).  
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Treatment with D-HG showed no significant effect on IκB expression (Figure 4.6 B).  
This result suggests that IL-12 suppression is not related to direct alterations in the NF-κB 
signaling pathway. Therefore, we investigated other signaling molecules related to NF-κB 
activity. 
 
4.1.3.2 HIF Expression  
 
Another signaling molecule associated with the regulation of IL-12 production by DCs is 
the hypoxia inducible factor (HIF). Hypoxia-inducible factors (HIFs) are regulators of 
hypoxic adaptation, regulating gene expression associated with glycolysis, erythropoiesis, 
angiogenesis, proliferation and stem cell function under low oxygen concentration. 
Additionally HIF-1α modulates dendritic cell maturation, activation and antigen-
presenting functions in combination with LPS 115. Degradation of HIF is regulated via 
prolyl-hydroxylases which have been reported to be modulated by HG 47. 
 
 
Figure 4.7. HIF involvement in IL-12 production by DCs. TLR4 pathway is activated by LPS. 
The activation of TLR4 induces the activity of Nuclear factor-κB (NF-κB), which leads to HIF-α 
accumulation, and consequently modulates the production of cytokines like IL-12, TNF and IL-6 
modified from Willam et al., 2014 116. HIF could be targeted by HG via prolyl-hydroxylase (PHD) 
47. 
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Figure 4.8. Expression of HIF-1α in DCs. iDCs were stimulated with LPS (100ng/ml) and 
treated with or without 10mM D-HG. After 24hrs of treatment cell pellets were lysed in RIPA 
buffer and analyzed by Western Blotting (n=3). Blots of 3 independent experiments are shown.  
 
HIF-1α expression was determined after 24hrs because basal HIF levels are stabilized 
after this period of time in LPS stimulated cells 117 in contrast to IκB-α where degradation 
occurs after 2 hours 118 in resting cells. 
The effect of LPS on HIF-1α was not consistent. Only in experiment 2 HIF-1α expression 
was induced after LPS stimulation, while in experiment 1 LPS stimulation even reduced 
HIF levels. No effect of LPS was determined in experiment 3. Moreover, incubation with 
HG (with both isoforms D/L-HG) also showed no reproducible effects (Figure 4.8).  
 
4.1.3.3 P-Akt and Akt Expression  
 
Akt is a serine/threonine-specific protein kinase that plays a key role in multiple cellular 
processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell 
migration. Once correctly positioned at the membrane via binding of Phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3), Akt can then be phosphorylated by its activating kinases. In 
turn Akt activates or deactivates other kinases as ERK or JNK. Downstream signaling 
pathways of Akt can directly regulate IL-12 production.  
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Figure 4.9. PI3-Kinase pathway and IL-12 production by DCs. PI3-kinase signaling pathway 
is activated by LPS binding to the TLR4 receptor which is coupled to the MyD88 complex, 
activation of PI3-Kinase leads to a signaling cascade of phosphorylation, resulting in the 
production of IL-12. Alternatively the MAPkinases can be activated via reactive oxygen species 
119 
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Figure 4.10. Expression of P-Akt and Akt in DCs. iDCs were stimulated with LPS (100ng/ml) 
with or without 10mM D-HG. After 24hrs of treatment phospholysates from cell pellets were 
prepared and protein expression analyzed by Western Blotting (n=4). A) Blots of three 
independent experiments are shown. B) Quantitative analysis of D-HG effect on P-Akt protein 
expression. C) Quantitative representation of D-HG effect on Akt protein expression. Statistical 
analysis was tested by Kruskal-Wallis test (*p≤0.05, ns not significant).  
 
LPS-induced maturation, increased the amount of p-Akt and reduced the Akt content at 
the same time, although statistical signficance was not reached. D-HG had no impact on 
these alterations. (Figure 4.10).  
This result suggests that IL-12 suppression triggered by D-HG is also not related to an 
impairment of the PI3/Akt signaling pathway. Next we analyzed the D-HG effect on the 
p38 signaling pathway.  
 
4.1.3.4 P-p38 and p38 Expression  
 
Because we were not able to observe any effect of D-HG on PI3/Akt signaling pathway, 
we proceeded to analyze whether the MAPK signaling pathway it is affected by D-HG 
treatment. p38 MAP kinases (α, β, γ, and δ) are members of the MAP kinase family that 
are activated by a variety of environmental stresses as inflammatory cytokines, 
lipopolysaccharides (LPS) and ROS 119. Dual specificity mitogen-activated protein kinase 
kinase 3 (MKK3) activates p38 MAPK by phosphorylation at threonine (Thr)180/tyrosine 
(Tyr)182 residues. Activated p38 MAPK phosphorylates and activates a signaling pathway 
involving a cascade of other kinases related to cytokine production 104.  
Immature DCs were cultured as previously described and stimulated with LPS in the 
presence or absence of 10mM D-HG for 24hrs. 
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Figure 4.11. Expression of p38 protein in DCs. iDCs were stimulated with LPS (100ng/ml) with 
or without 10mM D-HG. After 24hrs phospholysates from cell pellets were prepared and protein 
expression analyzed by Western Blotting (n=4). A) Qualitative representation of P-p38 expression 
on DCs, 3 independent experiments of 4 are shown. B and C) Quantitative determination of P-p38 
and p38 expression in DCs respectively, data represent the mean +/- SEM of 4 independent 
experiments. Statistical significance was performed with Kruskal Wallis Test (*p≤0.05, ns not 
significant). 
 
LPS had no significant impact on the expression of the phosphorylated form of p38 
protein, as well as the treatment with 10mM D-HG did not show a significant effect 
(Figure 4.11 A and B).  
Neither LPS treatment displayed a significant effect on p38 expression, nor addition of 
10mM D-HG exerted any additional impact (Figure 4.11 A and C).  
Taken together, LPS induced maturation had no effect on p38 expression or 
phosphorylation, thus this pathway seems to be of minor importance for DC maturation. 
Another signaling regulated kinase related with IL-12 production is ERK, hence we 
proceded to analyze whether the D-HG induced reduction in IL-12 secretion is related to 
an impairment of this signaling pathway. 
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4.1.3.5 P-ERK Expression  
 
Extracellular-signal-regulated kinases (ERKs) are involved in a variety of processes 
including the regulation of meiosis, mitosis, and postmitotic functions in differentiated 
cells. ERKs are known to activate many transcription factors, and some downstream 
protein kinases. Disruption of the ERK pathway is a common phenomenon in cancer. 
Phosphorylation of ERKs leads to the activation of their kinase activity. 
 
Figure 4.12. Expression of ERK protein in DCs. iDCs were stimulated with LPS (100ng/ml) 
with or without D-HG. After 24hrs phospholysates from cell pellets were prepared and protein 
expression analyzed by Western Blotting (n=3).  
 
ERK expression itself showed no consistent alterations upon LPS treatment. Interestingly, 
the expression of p-ERK seems to be affected by the treatment of LPS +D-HG in three of 
5 experiments. However the effect was not consistent as experiment 1 showed no impact 
on D-HG addition, experiments 2 showed an increased expression of p-ERK by D-HG, 
while experiment 3 showed a decrease although non-phosphorylated ERK expression was 
maintained independent of the treatment in all sets of experiment (Figure 4.12).  
These results suggest, ERK signaling pathway is also not involved in the observed IL-12 
suppression by the D-HG. Taken together, we did not detect any pronounced and 
consistent altertations in different kinase pathways related to IL-12 secretion. Therefore, 
other candidates were considered. We elucidated GPR related cAMP signaling, which is 
also important for IL-12 expression.   
 
4.1.3.6 GPR109a Expression  
 
G proteins are known to be expressed on DCs and regulate intracellular cAMP 
accumulation. Some of these proteins are: GPR81 (lactate receptor), GPR109 (butyrate 
and niacin receptor), GPR91 (succinate receptor) and GPR80/99 (ketoglutarate receptor). 
GPR109A, GPR109B and GPR81 receptors are activated by hydroxy-carboxylic acid 
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ligands. GPR109A has been reported to be expressed in immune cells such as monocytes, 
macrophages and dendritic cells 120. As GPR109A is activated by hydroxyl carboxylic 
acids and HG (D-2/L-HG) contains two carboxylic acid groups, we questioned ourselves 
whether GPR109A could be a possible receptor for HG on dendritic cells.  
With this in mind we decided to address the mRNA expression of GPR109a in iDCs in 
the presence or absence of HG and performed the same analysis in DCs stimulated with 
LPS in the presence or absence of HG. RNA from all treatment groups was isolated, and 
the expression of GPR109 was determined by real time PCR. 
 
Figure 4.13. Effect of HG on GPR109a expression. RNA expression was analyzed in iDCs 
treated with or without 10mM D/L-HG for 24hrs and in DCs stimulated for 24hrs with LPS in the 
presence or absence of 10mM D/L-HG. RNA was isolated and transcribed to cDNA for further 
GPR109A expression analysis by real time PCR. Data represent the mean +/- SEM of 3 
independent experiments, statistical analyses was performed with Kruskal Wallis Test (ns not 
significant).  
 
Immature dendritic cells showed low levels of GPR109A expression, which was not 
affected by the addition of D-HG. However, LPS significantly increased GPR109A 
expression, which was also observed in the presence of D-HG (Fig. 4.13). Nevertheless a 
clear trend towards a reduced expression in the presence of D-HG was detected. 
Therefore, we also analyzed the impact of L-HG and got the same results. As a changed 
expression of GPR109A could strongly affect IL-12 secretion, we investigated this 
pathway in more detail. For this set of experiments we used both enantiomers D-HG and 
L-HG. 
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4.1.3.6.1 Impact of GPR109A modulators  
 
 
 
Figure 4.14. Effect of nicotinic acid on IL-12 production by DCs. GPR109A signaling pathway 
is activated by Niacin, but effect of D-HG on GPR109A signalling is unclear.  
 
GPR109A has been reported to be expressed on DCs and related to cAMP levels which 
are directly associated with IL-12 levels. To demonstrate this relation we took a ligand for 
this receptor (niacin) and determined whether or not this has the same effect on IL-12 
secretion as HG.  
 
Figure 4.15. IL-12 production by DCs under HG and nicotinic acid treatment. iDCs were 
stimulated with LPS (100ng/ml), 10mM D-HG with and without 100µM nicotinic acid, 10mM L-
HG and nicotinic acid alone. After 24hrs supernatants were collected and analyzed by ELISA. 
Data represent the mean +/- SEM of 6 independent experiments. Statistical analysis was tested 
with Kruskal Wallis -Test (** p≤0.01, **** p≤0.0001, ns not significant). 
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We observed no effect on IL-12 production (Figure 4.15) by niacin, suggesting that GPR 
109A signaling is not responsible for IL-12 down regulation. Nevertheless, this does not 
rule out a possible involvement of cAMP in the D-HG induced restriction in IL-12 
secretion.  
 
4.1.3.7 Impact of cAMP modulating drugs on DCs 
 
During the evaluation of IL-12 modulatory signaling pathways we found no relationship 
between the pathways analyzed and the treatment with D-HG. Several reports suggest a 
relation between cyclic adenosine monophosphate (cAMP) levels and dendritic cell 
function. A variety of studies stipulated that cAMP-inducing factors (as Forskolin) inhibit 
IL-12 production from DCs 121,122. Forskolin is a rapid activator of adenylyl cyclase and 
has been used to increase intracellular cAMP levels.  
Taking this into consideration we differentiated dendritic cells and treated them with  
10mM D-HG, 100µM of cAMP analog and/or 10µM Forskolin.  
 
 
Figure 4.16. Effect of cAMP and cAMP modulators on IL-12 production by dendritic cells. 
Monocyte-derived iDCs were plated on 24 well plates (0.2x106 in 1ml), cells were treated with 
100ng/ml LPS, 10mM D-HG/L-HG, 10µM Forskolin, 100µM cAMP-Rp and DMSO to control 
for carrier effects. Data represent the mean +/- SEM of 6 independent experiments. Statistical 
analysis was tested with Kruskal Wallis Test. (*p≤0.05, ** p≤0.01, ns not significant).  
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In line with published data we observed a significant reduction in IL-12 production by 
Forskolin and cAMP analog (cAMP-Rp) addition (Figure 4.16), which was not attributed 
to DMSO related effects. Forskolin restricted IL-12 level was comparable to HG 
treatment. These results suggest that the effect of D-HG on IL-12 production could be 
associated with increased cAMP levels. As a consequence, intracellular cAMP 
concentrations were measured upon LPS treatment in the presence or absence of D-HG. 
4.1.3.7.1 cAMP Expression in Dendritic Cells  
 
In dendritic cells cAMP mediated signaling exerts a suppressive function on the immune 
response. High levels of intracellular cAMP downregulate IL-12 p40 mRNA expression 
and IL-12 p70 production in murine myeloid cells 121. 
 
In order to elucidate whether IL-12 downregulation by HG is related to cAMP levels in 
DCs, we treated iDCs with LPS 100ng/ml and 10µM Forskolin for 1 hour and measured 
cAMP levels. 
 
Figure 4.17. Effect of D-HG on cAMP levels. Monocytes- derived iDCs (5 x106/ml) were placed 
in FACS tubes and cells were treated with 100ng/ml LPS and/ or 10µM Forskolin. The cells were 
lysed and cAMP measurement was performed. Data represent the mean +/- SEM of 3 independent 
experiments. Statistical significance was tested with Kruskal Wallis Test. (*p≤0.05, ns not 
significant). 
 
Compared to unstimulated DCs cAMP levels were reduced when LPS was present, the 
addition of Forskolin did not increase cAMP levels in contrast to what was expected 
(Figure 4.17), indicating that the methodological approach was not appropriate.  
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4.1.4 The impact of HG on Mitochondrial Respiration 
 
During the last years it became more and more evident that metabolism is directly linked 
to immune cell function. Increased glucose metabolism but decreased mitochondrial 
respiration has been related to myeloid cell activation. Furthermore, increased cAMP, 
probably related to the inhibition of IL-12 can also activate the PKA signaling pathway 
which in turn increases mitochondrial respiration. Therefore, we analyzed whether D-HG 
induced IL-12 blockade might be associated with altered mitochondrial respiration in DCs.  
 
4.1.4.1 Impact of D-HG on Mitochondrial Respiration  
 
To elucidate if D-HG induces changes in mitochondrial respiration of DCs, we measured 
oxygen consumption of iDCs and DCs stimulated with LPS in the presence or absence of 
10mM D-HG.  
 
 
Figure 4.18. Oxygen consumption of DCs in the presence of D-HG. Monocyte-derived iDCs 
were seeded on a 24 well plate OxoDish® (PreSens Precision Sensing GmbH, Regensburg, 
Germany), activated with 100ng/ml LPS and treated with 10mM D-HG for 24hrs. Shown is the 
oxygen decline as a measure of oxygen consumption of 2 independent experiments as well as the 
respective IL-12 levels determined by ELISA.  
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In experiment 1 (Figure 4.18 Athe exposure to D-HG lowered oxygen levels compared to 
LPS treatment alone (more O2 consumption). Analyzing IL-12 levels in the supernatants 
revealed a high basal level of IL-12 and a strong reduction under D-HG treatment.  
Nevertheless, in the second experiment (Figure 4.18 B) D-HG treated DCs showed a 
lower oxygen consumption. However, IL-12 levels in the supernatant were very low and 
D-HG exerted no clear effect. For further clarification we decided to analyze 
mitochondrial respiration by a technology providing absolute values of oxygen 
consumption.  
4.1.4.2 The effect of D-HG on Mitochondrial Respiration analyzed by 
high resolution respirometry 
 
In order to evaluate the effect of D-HG on mitochondrial respiration in detail we used the 
classical respirometry, a technology that allows to measure the rate of respiration in a 
closed system thereby increasing the sensitivity.  
 
 
Figure 4.19. Oxygen consumption of DCs in the presence of D-HG. Monocyte-derived iDCs 
were placed in oxygraph chambers (1x106/ml) in culture medium. After stabilization of respiration 
D-HG or medium was added to the chambers and incubated for 10min. Then cells were activated 
with 100ng/ml LPS and oxygen consumption was monitored for 1hr. One representative 
experiment of 8 is presented.  
 
LPS stimulation significantly reduced oxygen consumption, which was completely 
prevented by D-HG (Figure 4.19 and 4.20).  
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Figure 4.20. Routine respiration of DCs in the presence of D-HG. Oxygraph chamber were 
filled with 1x106/ml monocyte-derived iDCs. After stabilization of respiration 10mM D-HG or 
medium was added to the chambers and incubated for 10 min. Then cells were activated with 
100ng/ml LPS and oxygen consumption was monitored for 1hr. Data represent the mean +/- SEM 
of 11 independent experiments. Statistical testing was performed with Kruskal-Wallis test. 
(*p≤0.05, **** p≤0.0001, ns not significant). 
 
ROUTINE respiration reflects the aerobic metabolic activity of the cells in culture 
medium. As the extent of the LPS induced reduction in ROUTINE respiration varied 
between the donors, we decided to analyze if the inhibition is related to the levels of IL-
12 secreted by DCs. We correlated the percental inhibition of ROUTINE respiration by 
LPS with IL-12 levels. 
 
Figure 4.21 Correlation of LPS induced inhibition in ROUTINE respiration with IL-12 
secretion by DCs. Percent of LPS inhibition was calculated dividing ROUTINE respiration after 
1hr of LPS addition by ROUTINE respiration observed before LPS addition. LPS induced 
inhibition of respiration was then correlated with IL-12 expression, 1.0 represent no inhibition by 
LPS. Statistical analysis was tested with linear regression test (*p≤0.05). R2 = 1 represent that the 
regression line perfectly fits the data. 
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The inhibition in basic respiration (ROUTINE) by LPS was not positively correlated with 
the levels of IL-12 produced.  
After 1 hour we investigated respiratory characteristics in more detail by applying 
oligomycin (ATP synthase inhibitor) to determine LEAK respiration (oxygen 
consumption to compensate for proton leak) followed by titration of an uncoupler to 
measure maximum capacity of the electron transfer system. Oxygen consumption not 
related to the respiratory complexes (residual oxygen consumption, ROX) was 
determined after rotenone (0,5µM) and myxothiazol (2,5µM) addition. All respiratory 
parameters were corrected for ROX. Mitochondrial oxygen consumption related to ATP 
production was calculated as the difference between ROUTINE and LEAK respiration 
(R-Oligo).  
 
Figure 4.22 Impact of D-HG on Leak and ATP related oxygen consumption in DCs. 
Oxygraph chambers were filled with 1x106/ml monocyte-derived iDCs, after stabilization of 
respiration, 10mM D-HG or medium was added to the chambers and incubated for 10min. Then 
cells were activated with 100ng/ml LPS and oxygen consumption was monitored for 1hr. Leak 
respiration was determined after the addition of oligomycin and subtracted from ROUTINE 
respiration to calculate oxygen consumption related to ATP production. Data represent the mean 
+/- SEM of 11 independent experiments. Statistical significance was tested by Kruskal-Willis Test. 
(*p≤0.05, ** p≤0.01, ns not significant). 
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Leak was not affected by D-HG but oxygen consumption related to ATP production was 
significantly reduced after LPS addition and this effect was prevented by the addition of 
D-HG (Figure 4.22). The capacity of the electron transfer system was also higher in D-
HG treated cells (Figure 4.23). These data point towards reduced substrate flux into 
mitochondria upon stimulation with LPS, which was prevented in D-HG treated DCs. 
 
Figure 4.23 Electron Transfer System capacity (ETS) is affected by D-HG in DCs. Oxygraph 
chambers were filled with 1x106/ml monocyte-derived iDCs, After stabilization of respiration D-
HG or medium was added to the chambers and incubated for 10 min. Then cells were activated 
with 100ng/ml LPS and oxygen consumption was monitored for 1hr. After addition of oligomycin, 
FCCP was titrated up to maximum uncoupled respiration. Data represent the mean +/- SEM of 11 
independent experiments. Statistical significance was performed by Wilcoxon Test. (*p≤0.05, ns 
not significant).  
 
4.1.4.3 The impact of D-HG on the content of Mitochondrial Respiratory 
Complexes  
 
In order to elucidate whether a change in the complexes of the mitochondrial respiratory 
system could be associated with the observed LPS effect and the blockade by D-HG, we 
analyzed respiratory complexes with an antibody mixture detecting all complexes.  
Monocytes-derived iDCs were incubated for 1hr with LPS in the presence or absence of 
D-HG, phospholysates were generated and analyzed by Western blot as previously 
described in section 3.6.  
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Figure 4.24. Respiratory complexes on DCs treated with D-HG. Monocytes-derived iDCs 
were seeded (2.5x106 cells on 4ml) in 6 well plates, incubated for 1hr with LPS and D-HG, 
phospholysates were prepared and analyzed. Heart mouse lysate was used as positive control. 
Complex I (CI) with Molecular Weight (MW) of 20KD, Complex II (CII) with MW of 30KD, 
Complex III (CIII) with MW of 48KD, Complex V (CV) with MW of 55KD.  
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Complex III and V displayed no changes by the addition of LPS or D-HG. Complex I and 
II seemed to have a slight increase in protein expression by the addition of D-HG, 
nevertheless the result was not consistent. In addition we were not able to observe 
complex IV which should be present at 40KD. Further studies should be performed in 
order to confirm D-HG effects. 
Taken together, we observed a reduction of ROUTINE respiration, mitochondrial 
capacity and oxygen consumption related to ATP production by LPS which was 
prevented by D-HG.  
 
Rapid changes in mitochondrial contents do not seem to be an underlying mechanism 
explaining the effect of LPS on respiration and the prevention by D-HG. 
To analyze whether the reduction in mitochondrial respiration is directly linked to IL-12 
production we investigated whether mitochondrial inhibition is sufficient to increase IL-
12 secretion. Rotenon, a complex I inhibitor was used as well as oligomycin, blocking 
mitochondrial ATP production. 
 
 
Figure 4.25. Effect of oligomycin and rotenon on IL-12 production by DCs. Monocyte- 
derived iDCs were plated on 24 well plates (0.2x106 in 1ml), cells were treated with 100ng/ml 
LPS, 10mM D-HG/L-HG, 0.5µM oligomycin or 0.1µM rotenon, 0.5µM EtOH served as carrier 
control. Data represent the mean +/- SEM of 7 independent experiments. Statistical significance 
was tested by Kruskal Wallis Test. (*p≤0.05, ** p≤0.01, **** p≤0.0001, ns not significant). 
 
Cytokine production of DCs was not negatively affected by the treatment with oligomycin 
or rotenone. Both compoounds exerted only a slight effect on IL-12 production and this 
effect was not statistically significant. However, both inhibitors could not rescue the HG 
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induced reduction in IL-12 secretion, thus inhibition of mitochondrial respiration is not 
sufficient to increase IL-12 levels.  
 
4.1.4.4 The impact of CsA on IL-12 production 
 
Mitochondria are involved in cellular Ca2+ homeostasis. Activation of immune cells 
results in the release of Ca2+ from the endoplasmatic reticulum into the cytosol and 
subsequently results in the activation of Ca2+ influx from the extracellular space. 
Cyclosporine A (CsA) blocks mitochondrial calcium efflux and allows mitochondria to 
accumulate a large amount of calcium123 thereby probably reducing cytosolic calcium 
which has been shown to reduce IL-12 secretion in myeloid cells 124. Ca2+ accumulation 
induces dephosporylation of mitochondrial proteins; more Ca2+ is related to ahigher 
respiration. 
Taking this in consideration we analyzed whether CsA can modulate the HG induced 
reduction in IL-12 secretion.  
 
Figure 4.26. Effect of CsA on IL-12 production by dendritic cells. iDCs were activated with 
100ng/ml LPS and treated with 10mM D/L-HG, CsA 32pM, and the combination of them. After 
24hrs supernatants were collected and IL-12 was measured by ELISA. Data represent the mean 
+/- SEM of 7 independent experiments. Statistical significance was performed by One Way 
Anova. *** p≤0.001,**** p≤0.0001, ns not significant). 
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Addition of D-HG or L-HG significantly reduced IL-12 production (Figure 4.26). DCs 
treated with CsA and LPS displayed a higher IL-12 production compared to LPS alone. 
Nevertheless this increase was not statistical significant due to donor variation. When 
CsA was combined with LPS+D-HG, IL-12 production was no longer statistically 
reduced compared to LPS  
In order to analyze if CsA could affect the mitochondrial phenotype we evaluated the 
impact of CsA in combination with D-HG on Routine respiration.  
 
Figure 4.27. Routine respiration and oxygen consumption related to ATP production of DCs 
in the presence of CsA. Oxygraph chamber was filled with 1x106/ml Monocyte-derived iDCs, in 
2ml final volume. Cells were activated with 100ng/ml LPS and treated with 10mM D-HG and/or 
32pM CsA for 1hr. A) Routine respiration, B) Oxygen consumption related to ATP production. 
Data represent the mean +/- SEM of 7 independent experiments. Statistical significance was 
performed by Kruskal-Wallis (ns not significant).  
 
Addition of LPS reduced O2 consumption even though this effect was not statistically 
significant in this set of experiments. D-HG addition blocked the effect of LPS. After 1h 
CsA could not alter the effects of LPS or the combination of LPS and HG. (Figure 4.27 
A/B and 4.28).  
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Figure 4.28 Percentual representation of LPS inhibition on DCs treated with CsA and D-HG. 
Cells were activated with 100ng/ml LPS and treated with 10mM D-HG and/or 32pM CsA for 1hr. 
Data represent the mean +/- SEM of 7 independent experiments. Statistical significance was 
performed by Kruskal-Wallis (ns not significant). 
 
Results observed in figures 4.27 and 4.28 investigated the effects after one hour treatment. 
These results revealed no effect on respiration by LPS+CsA in comparison with 
DCs+LPS. Nevertheless in two cases we prolonged the measurement for 2 hours and 
observed a clear effect in the presence of CsA.  
 
Figure 4.29. Routine respiration of DCs in the presence of CsA after 2hrs. Oxygraph chamber 
was filled with 1x106/ml Monocyte-derived iDCs, in 2ml final volume. Cells were treated with 
32pM CsA, after stabilization 10mM D-HG or medium was added and minutes later cells were 
activated with 100ng/ml LPS, ROUTINE respiration was monitored for 2hr. 1 experiment of 2 is 
shown. 
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LPS addition triggered a drop in respiration, which was blocked by D-HG. When D-HG 
was combined with CsA initially, the drop in respiration was not rescued (Figure 4.27). 
However, after 2 hours, respiration under CsA + D-HG showed a decline similar to LPS 
(Figure 4.29). These results point towards an attenuation of the D-HG effect (Figure 4.29). 
To confirm these results, more experiments should be performed.  
 
4.1.4.5 Impact of D-HG on lactate secretion 
 
Our data point towards a change in substrate flux. As it has been described that activation 
of myeloid cells increases their glycolytic activity, we analyzed lactate levels in 
supernatants of LPS stimulated DCs with and without D-HG.  
  
 
 
Figure 4.30 Impact of D-HG on lactate secretion in supernatants of activated DCs. iDCs 
were treated with LPS 100ng/ml and 10mM D-HG for 24 hours, the supernatants were collected 
and lactate levels were measured enzymatically. Data show the mean +/- SEM of 5 independent 
experiments. Statistical significance was tested by One Way Anova. (*p≤0.05, ** p≤0.01, ns not 
significant).  
 
Figure 4.30 shows that iDCs treated with LPS displayed an increased lactate secretion. 
Under D-HG treatment this increase was less pronounced. Taken together, these results 
suggest that LPS shifts the metabolism from oxidative phosphorylation to glycolysis. D-
HG prevents these metabolic alterations, which might contribute to reduced IL-12 levels.  
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4.1.5 Gene Expression in DCs treated with D-HG. 
 
Next we investigated whether D-HG could affect gene expression. For this, we took 
monocytes and differentiated them into DCs. DCs were then exposed to 10mM D-HG for 
the next 24 hours. We used 10mM α-ketoglutaric acid (Di-keto) as a control as D-HG is 
structural closely related to ketoglutarate and represents a competitive inhibitor of α-
ketoglutarate-dependent dioxygenases 125. Because of this we wanted to separate possible 
effects based on this similarity of HG and Di-keto on gene expression from effects which 
are only induced by HG. Next, we lysed the cells and performed RNAseq analysis 
(RNAseq analyses was performed by Prof. Dr.Michael Rehli, Depart. of Internal 
Medicine III).  
The mean +/- SEM of 3 independent experiments per treatment were compared for the 
following conditions: -LPS vs LPS, LPS vs LPS plus D-HG, LPS vs LPS plus Di-Keto. 
We only considered genes that were regulated by LPS. Genes that are significantly 
regulated by LPS and D-HG in comparison to LPS alone are presented in Table 4.1 and 
4.2. We excluded genes that are similiarily regulated by HG and Di-Keto in the presence 
of LPS Genes that showed a Log change ≥ 0.6 for LPS vs LPS plus HG but a Log change 
<0.6 in the comparison LPS vs LPS plus Di-Keto were considered as upregulated genes. 
Genes with a Log change <0.6 for LPS vs LPS plus D-HG and no effect of LPS vs LPS 
plus Di-Keto comparisons were considered downregulated. 
 
4.1.5.1 Genes Upregulated with D-HG 
 
Interestingly the majority of genes (213), were regulated in a similar way by HG and Di-
Keto.Table 4.1 shows the 6 genes that were differentially only upregulated by D-HG but 
not Di-Keto on mRNA level. Among those 6 genes a member of a transmembranal 
receptor family that couple to G protein ( F2RL2) was upregulated by D-HG. Furthermore 
CXCR5, a cytokine receptor involved in the modulation of B-cell differentiation was also 
upregulated by D-HG presence.  
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Table 4.1 Genes Upregulated in DCs by D-HG.  
Symbol Transcript Length 
Transcript 
Type  
BMP6 2780 protein_coding 
Bone morphogenetic protein 6;induces cartilage and 
bone formation 
 
CXCR5 4431 protein_coding 
Receptor 5; cytokine receptor that binds to B-
lymphocyte chemoattractant (BLC). Involved in B-
cell migration into B-cell follicles. May have a 
regulatory function in Burkitt lymphoma (BL) 
lymphomagenesis and/or B-cell differentiation 
 
F2RL2 3429 protein_coding 
Coagulation factor II (thrombin) receptor-like 2; 
Receptor for activated thrombin coupled to G proteins 
that stimulate phosphoinositide hydrolysis 
 
MYO1B 9527 protein_coding 
Myosin IB; Motor protein that may participate in 
process critical to neuronal development and function 
such as cell migration, neurite outgrowth and 
vesicular transport 
 
PLAT 6618 protein_coding 
Plasminogen activator, tissue; it plays an important 
role in tissue remodeling and degradation, in cell 
migration and many other physiopathological events. 
 
SERPINB2 2748 protein_coding 
Serpin peptidase inhibitor, clade B (ovalbumin), 
member 2; Inhibits urokinase-type plasminogen 
activator. 
 
 
4.1.5.2 Genes downregulated with D-HG  
 
When we analyzed the genes which were downregulated by D-HG, 191 genes were 
downregulated in a similar way by HG and Di-keto. Furthermore only 3 genes were 
reduced by HG but not Di-Keto. HG suppressed expression of IL-18, which is a pro-
inflamatory cytokine, resembling the function of IL-12. In a medical thesis126 and my 
master thesis the impact of Di-Keto on IL-12 was already investigated and we found no 
effect excluding the possibility that keto-dependent dioxygenases are involved in the 
regulation of IL-12. 
In addition, we also observed a down regulation in DNAH11, gene involved in ATPase 
activity, listed in Table 4.2.  
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Table 4.2 Genes Downregulated in DCs by D-HG.  
Symbol ID Transcript length 
Transcript 
type 
 
RP11-1D12.1 769 sense_intronic  
C12orf79 
(LINC01619) 3642 protein_coding 
Long Intergenic Non-Protein Coding 
RNA 1619. 
DNAH11 15998 protein_coding 
Dynein, axonemal, heavy chain 11; 
Dynein has ATPase activity; the force-
producing power stroke is thought to 
occur on release of ADP.  
RP11-519G16.3 3886 Antisense  
IL18 2628 protein_coding 
Interleukin 18 (interferon-gamma-
inducing factor); Augments natural killer 
cell activity in spleen cells and stimulates 
interferon gamma production in T-helper 
type I cells. 
 
RP11-404F10.2 4121 Antisense  
 
 
4.1.6 The role of HG on LPS-induced DC maturation 
 
LPS is not only a strong activation stimulus of myeloid cells but can also induce the 
maturation of immature DCs into mature DCs. During DC maturation, immature DCs 
loose their high capacity for phagocytosis but gain the ability to present antigens to T 
cells, which is crucial for the adaptive immune response. Several marker proteins, which 
are important for antigen presentation, are upregulated by LPS such as CD80 or CD83. In 
order to further investigate effects of D-HG on DCs, we analyzed the expression of these 
co-stimulatory molecules that increase during DC activation such as CD80, CD86, CD83, 
HLA-DR (molecules related to antigen presentation) and CD1a (related to the lipid 
presentation). DCs were differentiated from monocytes, stimulated with LPS for 24h in 
the presence or absence of 10mM D-HG.  
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Figure 4.31. Effect of HG on DC maturation. DCs were differentiated from monocytes for 7 
days with IL-4 and GM-CSF. After this differentiation process, iDCs were stimulated with LPS 
(100ng/ml) and 10mM D/L-HG for another 24hrs. Maturation markers were evaluated by flow 
cytometry.  
 
The presence of HG during the maturation process (day 7 to day 8) did not affect the 
expression of HLADR, CD80, CD86, CD83 or CD1a (Figure 4.31).  
 
4.1.7 The impact of HG on the differentiation of DCs 
 
Next, we were interested to elucidate whether the presence of HG during the whole 
differentiation process would inhibit this differentiation process and lead to an even 
stronger impact on LPS-induced IL-12 secretion. Therefore, DCs were differentiated in 2 
different settings: first, monocytes were differentiated for 7 days and stimulated at day 7 
with 100ng/ml LPS and D-HG for 24hrs, second, monocytes were differentiated into DCs 
with D-HG from the beginning of the differentiation process for 7 days and then activated 
with LPS for last 24 hours. First we analyzed whether IL-12 production is affected in a 
similar manner as in our previous experiments.  
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Figure 4.32. Effect of HG on DC IL-12 secretion. Monocytes were differentiated in 2 settings, 
A) addition of LPS+D-HG during activation process (day 7-8), B) addition of D-HG from day 0 
during the whole differentiation process, and at day 7, 100ng/ml LPS was added. Data show the 
mean +/- SEM of 3 independent experiments. Supernatants were collected after 8 days of culture 
and ELISA was performed. 
 
The presence of D-HG during the differentiation process affected the capacity of the cells 
to produce IL-12 much stronger compared to the addition of D-HG only during activation. 
IL-12 secretion was almost abolished when D-HG was added during differentiation 
(Figure 4.32).  
 
In order to further investigate effects of D-HG on the differentiation of DCs, surface 
markers involved in differentiation such as HLA-DR (molecule related with antigen 
presentation) and CD1a (related to lipid presentation) were stained on DCs differentiated 
in the presence or absence of 10mM D-HG without LPS stimulation.  
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Figure 4.33. Impact of D-HG on the differentiation of monocytes into immature DC. 
Monocytes were differentiated with IL-4 and GM-CSF for 7 days. The figure represents gating 
strategy and histogram plots of iDCs (7 days culture) for CD1a and HLA-DR expression in 
absence (upper panel) or in presence (lower panel) of D-HG during the differentiation process. 
Expression of differentiation markers were evaluated by flow cytometry. One representative 
experiment out of three is presented. 
 
iDCs treated with D-HG during the entire differentiation process showed a reduced HLA-
DR expression while the contrary holds true for CD1a (Figure 4.33). A 5-fold increase of 
CD1a expression was observed in D-HG treated cells in comparison to untreated cells 
(cells without D-HG treatment).  
 
Next we differentiated iDCs under the same settings mentioned on Figure 4.33 but in this 
case cells were activated for 24hrs with 100ng/ml LPS.  
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Figure 4.34. Impact of D-HG on DC maturation. Monocytes were differentiated with IL-4 and 
GM-CSF for 7 days in the absence (upper panel) or presence(lower panel) of 10mM D-HG. On 
day 7 iDCs were stimulated with LPS for 24hrs. One representative experiment out of three is 
presented.  
 
The downregulation of HLA-DR and the upregulation of CD1a (Figure 4.34) by HG was 
still observed after DC maturation with LPS (Figure 4.35, Figure 4.36), (Figure 4.35, 
4.36). Therefore, LPS did not overcome the effect of 10mM D-HG.  
 
In summary, long term treatment of DCs with D-HG exerted an even stronger impact on 
IL-12 levels compared to short -term effects. Furthermore HG changed the surface marker 
expression.  
Further investigations are necessary to elucidate the long-term impact of D-HG on DCs 
differentiation.  
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4.2 Glioblastoma cell lines 
 
We found a strong impact of HG on DC metabolism. It has been reported, that IDH 
mutations and HG have also an impact on the prognosis of patients with glioblastomas. 
Based on these findings we analyzed whether D-HG has also an impact on mitochondrial 
respiration of tumor cells. We investigated the impact of D-HG on the respiration of 
different glioma cell lines.  
4.2.1 U87  
 
We started to analyze the U87 cell line, a commonly studied grade IV glioma cell line, 
which was obtained from a stage four 44 year-old cancer patient and is characterized by 
epithelial morphology 127.  
 
4.2.1.1 High resolution respirometry of U87 
 
We analyzed the effect of D-HG on glioblastoma cell respiration in detail by high-
resolution respirometry using a classical respirometric approach. 
 
 
Figure 4.35. Routine respiration of U87 in the presence of D-HG. Oxygraph chambers were 
filled with 1x106/ml U87 cells in 2ml final volume. After stabilization of respiration D-HG or 
medium was added to the chambers and oxygen consumption was monitored for 1hr. Data 
represent the mean +/- SEM of 3 independent experiments. Statistical significance was tested by 
Wilcoxon Test. (*p≤0.05, ns not significant).  
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In figure 4.35 we observed no significant effect on the O2 consumption by the addition of 
D-HG. After 1 hour we investigated respiratory characteristics in more detail by applying 
oligomycin (ATP synthase inhibitor) to determine LEAK respiration followed by titration 
of an uncoupler to measure maximum capacity of the electron transfer system. All 
respiratory parameters were corrected for residual oxygen consumption rates, determined 
after the addition of rotenone and myxothiazol.  
 
          
Figure 4.36. Impact of D-HG on ATP related oxygen consumption U87 cells. Oxygraph 
chambers were filled with 1x106/ml U87 cells in 2ml final volume. After stabilization of 
respiration D-HG or medium was added to the chambers and oxygen consumption was monitored 
for 1hr. Leak respiration was determined after the addition of oligomycine and subtracted from 
ROUTINE respiration to calculate oxygen consumption related to ATP production. Data represent 
the mean +/- SEM of 3 independent experiments. Statistical significance was tested by Wilcoxon 
Test. (*p≤0.05, ns not significant).  
 
Oxygen consumption related to ATP production was not affected by the addition of D-
HG. These results suggest that D-HG has no immediate effect on U87 respiration (Figure 
4.36). However, we cannot exclude an impact after a prolonged incubation time. Further 
experiments should be performed in order to elucidate long-term effects of D-HG on 
mitochondrial respiration of U87 cells. 
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4.2.2 TP365 
 
4.2.2.1 High resolution respirometry of TP365 
 
We then analyzed the effect of D-HG on a second glioblastoma cell line (TP365 under 
low glucose medium.  
 
 
Figure 4.37. Routine respiration of TP365 in the presence of D-HG. Oxygraph chambers were 
filled with 1x106/ml TP365 cells in 2ml final volume. After stabilization of respiration D-HG or 
medium was added to the chambers and oxygen consumption was monitored for 1hr. Data 
represent the mean +/- SEM of 3 independent experiments. Statistical significance was tested by 
Wilcoxon Test. (*p≤0.05, ns not significant).  
 
In TP365 we observed a trend for a reduction in O2 consumption under D-HG treatment 
although statistical significance was not reached (Figure 4.37). We then analyzed whether 
D-HG triggers an effect on oxygen consumption related to ATP production.  
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Figure 4.38. Impact of ATP related oxygen consumption in TP365 cells. Oxygraph chambers 
were filled with 1x106/ml TP365 cells in 2ml final volume. After stabilization of respiration D-
HG or medium was added to the chambers and oxygen consumption was monitored for 1hr. Leak 
respiration was determined after the addition of oligomycine and subtracted from ROUTINE 
respiration to calculate oxygen consumption related to ATP production. Data represent the mean 
+/- SEM of 3 independent experiments. Statistical significance was performed by Wilcoxon Test. 
(*p≤0.05, ns not significant).  
 
Although not significant, we again found a trend of reduced oxygen consumption related 
to ATP production in the TP365 cell line in the presence of D-HG.  
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5. Discussion  
 
Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate into 
α-ketoglutarate (α-KG). IDH1 and IDH2 are obligate homodimers and use nicotinamide 
adenine dinucleotide phosphate (NADP+) as a cofactor whereas IDH3 exists as 
heterotetramer and uses nicotinamide adenine dinucleotide (NAD)128. IDH2 and IDH3 are 
located in the mitochondria, whereas IDH1 is located in the cytosol. Together with the 
pentose pathway IDH1 and IDH2 enzymes are the most important source of NADPH. 
Point mutations in isocitrate dehydrogenase (IDH) 1 and 2 are frequently found in 
neoplasias including acute myeloid leukemia (AML) and glioma. Data from glioma 
patients showed a positive correlation between mutated IDH and overall survival 129 
whereas the prognostic impact of IDH mutations in AML varies across studies. A 
retrospective analysis by DiNardo et al. found no impact of IDH mutation status on 
overall survival in patients with AML 130. The opposite is observed in a study of more 
than 800 AML patients 128. Here IDH mutations constituted a poor prognostic factor in a 
subgroup of cytogenetically normal AML patients with mutated NPM1 without FLT3-
ITD.  
IDH mutations were mapped structurally to key residues within the active site, 
speciﬁcally the R132 codon in IDH1, and the R172 and R140 codons in IDH2. All 
mutations are generally heterozygous, suggesting a gain of function as a possible cancer 
mechanism. In line it has been shown that mutated IDH gains the neomorphic ability to 
convert α-KG into the oncometabolite D-2-hydroxyglutaric acid (D-HG). IDH mutations 
suppress hematopoietic differentiation in leukemia models131. However, little is known 
how HG can affect non-malignant hematopoietic cells.  
As a first step to address the impact of HG on non-malignant hematopoietic cells, we 
investigated whether human primary myeloid cells would take up HG. For this purpose 
we incubated monocyte-derived DCs with HG and determined intracellular levels of HG 
by mass spectrometry analysis in the Institute of Functional Genomics in Regensburg.  
DCs treated with LPS exhibited low endogenous levels of HG, but incubation with 10mM 
D-HG resulted in uptake of extracellular D-HG and 100 fold increased levels in 
intracellular HG. This demonstrated the capacity of DCs to uptake HG. Recently we 
could show that also primary human T-cells can uptake HG 132. At physiological pH, HG 
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exists as hydrophilic dicarboxylate anion and most likely requires specific transport 
systems to translocate across membranes. Several possible receptors for D-HG and L-HG 
have been tested in oocytes. From these investigations D-HG and L-HG were substrates 
of the organic anion transporters OAT1, OAT3, OAT4 and the sodium dicarboxylate 
cotransporter 3 (NaDC3) 133. Further studies should address the expression of those 
transporters in human myeloid and lymphoid cells to clarify whether these transporters 
are possibly involved in HG transport in primary hematopoietic cells.  
5.1 Effect of HG on the short term LPS response of 
immature DCs  
 
Dendritic cells are the most important link between innate and adaptive immunity. They 
capture antigens and present them to T cells, which leads to T cell activation and 
polarization. IL-12 levels secreted by dendritic cells have an important role in the 
regulation of a T cell response. High levels of IL-12 induce a Th1 response, whereas low 
IL-12 and high IL-10 secretion leads to Th2 differentiation 134.  
We studied the impact of D-HG on the LPS-stimulated cytokine response of human 
monocyte-derived DCs. IL-12 p70 was significantly decreased in supernatants of 
stimulated DCs when LPS and HG were added simultaneously. In contrast, other 
cytokines were not changed or even up regulated (IL-10) in the presence of D-HG. IL-12 
protein is a dimer composed of two subunits. Therefore, we analyzed the expression of 
both subunits by flow cytometry. D-HG did not affect the expression of the p35 subunit 
whereas p40 was clearly reduced indicating a selective regulation of this gene. In a 
previous work, the transcriptional regulation of p35 and p40 was analyzed after 4h 
stimulation with and without D-HG and the data indicate a statistically not significant 
impact of HG on the transcription of both subunits in DCs 126.  
We also tested whether the enantiomer of D-HG, L-HG, would also modulate IL-12 
secretion. Interstingly also L-HG inhibited IL-12 secretion by DCs. Most cancer-
associated IDH mutations seem to be associated with elevation of the D-enantiomer rather 
than the L-enantiomer, however in kidney tumors elevations of the L-enantiomer of HG 
has been described 135. Accumulation of L-HG is not based on an IDH mutation in renal 
cell carcinoma, but mediated by reduced expression of L-HG-dehydrogenase, which 
metabolizes L-HG back to α-KG. Therefore, not only D-HG but also L-HG represents an 
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oncometabolite even though the underlying mechanisms of elevation are different. What 
is more, in breast carcinoma it has been shown that independent of an IDH mutation, 
MYC activation and glutamine metabolism correlates with elevated HG levels and poor 
prognosis136. Hence, different mechanism can lead to elevated HG levels in tumor tissues 
dependent on the cancer type.  
As IL-12 is not only a marker for DC activation but also a marker for successful 
differentiation of DCs, we hypothesized that D-HG might suppress the immune response 
by altering the differentiation, activation and antigen presentation of DCs, resulting in 
reduced T cell activation and the capacity of tumor cells to escape the effects of the 
immune surveillance.  
In a next set of experiments we analyzed the impact of D-HG on the final maturation 
process of monocyte-derived DCs, which can be induced in vitro by incubation of 
immature DCs with LPS. For this purpose immature DCs were generated starting with 
human monocytes isolated from peripheral blood. After 7 days of differentiation with 
GM-CSF and IL-4, cells were incubated for another 24hrs with LPS to induce maturation. 
When D-HG (10mM) was added during the maturation no change in the expression of 
maturation markers such as CD80, CD86 or CD83 occurred indicating that the LPS-
induced maturation response was not altered by D-HG even though LPS-induced IL-12 
secretion was disturbed.  
5.2. Long term effects of HG on DC differentiation 
 
 
Next we investigated the impact of D-HG after long term incubation with D-HG during 
the 7 day differentiation process from monocytes to DCs. After 7 days we analyzed 
surface antigens of immature DCs. In parallel, DCs were treated with LPS for another 
24hrs and we analyzed surface markers and IL-12 secretion. As analyzed by flow 
cytometry, immature DCs showed lower surface expression of HLA-class II molecules 
(HLA-DR) and increased levels of CD1a when HG was present during the differentiation 
process. Furthermore, suppression of IL-12 secretion was much stronger after long term 
incubation of DCs with HG and subsequent stimulation with LPS. The downregulation of 
HLA-class II molecules and the strong reduction of IL-12 secretion may lead to a 
“tolerogenic” DC phenotype with decreased ability of antigen presentation and T-cell 
activation.  
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In conclusion, our results indicate that the oncometabolite D-HG impairs the APC 
function of DCs by down regulation of HLA-class II, as well as IL-12 secretion, which 
potentially may contribute to the immune escape of tumor cells in a tumor environment 
with HG accumulation.  
5.3. Impact of HG on TLR signaling  
 
 
Toll-like receptors (TLRs) are receptors expressed by cells of the innate immune system 
that are stimulated by bacteria, viruses and fungi. LPS is one of the best studied 
immunostimulatory components of bacteria and stimulates TLR4. Upon LPS recognition, 
TLR4 recruits downstream adaptors and triggers signaling pathways which finally lead to 
the activation of transcription factors 137. IκB kinase and MAPK (mitogen-activated 
protein kinase) pathways are activated.  
In order to elucidate underlying mechanisms responsible for the effect of D-HG on DCs 
activity, we analyzed TLR4 signaling pathways, IκB, P-Akt, P-p38, ERK, and HIF by 
western blot analyses as these pathways are crucial for the regulation of IL-12 production. 
DCs were treated with D-HG and stimulated with 100ng/ml LPS. First of all we 
investigated the NF-κB pathway. IκB-phosphorylation leads to the degradation of IκB 
proteins and subsequent activation of NF-κB. After 1h LPS-stimulation IκB was clearly 
degraded and D-HG had no effect on its degradation suggesting that the NF-κB pathway 
is not altered by D-HG.  
Furthermore, LPS raises the level of hypoxia-inducible factor-1α (HIF-1α) in 
macrophages, and HIF-1α promotes the production of inflammatory cytokines, such as 
IL-6 and IL-12 138. Additionally to these reports, high levels of cellular HG have been 
reported to lead to the hydroxylation of HIF-1α, thereby decreasing HIF expression. In 
addition to these findings, HG has been reported to competitively inhibit the binding of α-
KG to several histone demethylases, including JmjC-domain-containing histone 
demethylase proteins (JHDM) leading to a widely aberrant histone methylation profile 125. 
Likewise, it has been reported that HG acts as an inhibitor of hydroxymethylases like 
TET methylcytosine dioxygenases (TET) 1 and 2, involved in DNA demethylation 47. 
However, in our experiments we were neither able to detect consistent upregulation of 
HIF after LPS stimulation nor an effect of D-HG. Further analysis elucidating an effect of 
D-HG effect on the methylation profile of DCs is currently addressed in another PhD 
thesis.  
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Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) 
kinases have also been demonstrated to be involved in the regulation of LPS-stimulated 
IL-12 gene expression. While p38 promotes induction of IL-12 mRNA in macrophages, 
ERK activation suppresses LPS-mediated IL-12 transcription 139. Again no effect of D-
HG could be found. 
Conflicting results have been published regarding the LPS-triggered activation of 
PI3K/Akt pathway. Fukao et al. reported that it negatively regulates LPS-induced IL-12 
production in murine DCs 140 but Utsugi et al. described a positive impact of this pathway 
on human monocyte-derived cells 141. In our experiments P-Akt was only slightly 
upregulated by LPS and D-HG had no impact on the expression level. 
In summary all studied pathways triggered by LPS were not significantly changed by D-
HG treatment and cannot explain its negative impact on IL-12 production. 
5.3.1 Impact of G-Protein-coupled receptors and cAMP on IL-12 
production 
 
Unfortunately we were not able to demonstrate that D-HG disrupts or modulates the 
mentioned signaling pathways; therefore we asked whether the D-HG effect observed on 
IL-12 levels could be related to its binding/signaling via G-proteins as a group of G 
protein-coupled receptors (GPCR) serve as hydroxycarboxylic acid receptors 120 and 
therefore could represent possible receptors for D-HG. 
G-proteins have been shown to play a role in the cytokine production of myeloid cells. 
Especially GPR109A has been reported to be involved in the suppression of IL-12 
regulation in macrophages 142. With this in mind we decided to adress the expression of 
GPR109A in DCs treated with D-HG. Monocytes were differentiated for 7 days and the 
impact of HG on GPR109A expression was analyzed in iDCs and LPS matured DCs. We 
were able to demonstrate that immature DCs already express GPR109A and that mRNA 
expression is up regulated during the maturation of DCs by LPS. Addition of D-HG 
modestly reduced GPR109A expression. To elucidate whether a stimulation of GPR109A 
exerts a similar reduction on IL-12 secretion as HG, we applied niacin. In contrast to 
previous reports with macrophages 142 we found no effect on IL-12 production by the 
GPR109A ligand niacin, which excludes that HG signals via GPR109A in human DCs. 
Therefore macrophages and DCs may have different suceptibilty regarding niacin 
treatment. 
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Several reports show a relation between cyclic adenosine monophosphate (cAMP) and 
DC function 122,143,144. It has been shown that Forskolin, a cAMP inducing factor, inhibits 
IL-12 production 122. Thus we treated DCs with a cAMP analog, and Forskolin in 
comparison to D-HG, In line with previous observations 122 we found a significant 
reduction in IL-12 production by the addition of cAMP and forskolin similar to the impact 
of HG. These results indicated that IL-12 reduction by D-HG could be associated with an 
increase in cAMP levels. However, we were not able to measure increased cAMP levels 
in DCs even with Forskolin as positive control stimulus, which indicates that the test 
system was not reliable. Therefore, these analyses have to be repeated with another 
method.  
5.4 The role of HG on Mitochondrial Respiration and 
lactate production of Dendritic Cells  
 
cAMP plays an important role in PKA signaling pathway activation, which has been 
reported to modulate the activation of mitochondrial respiration 145–147. Moreover, several 
studies have shown effects of HG on mitochondrial respiration 45,148,149. Furthermore, 
metabolic alterations have been implicated in the activation of immune cells. Therefore 
we wondered whether IL-12 inhibition by HG could be associated with altered 
metabolism in DCs. A metabolic shift from OXPHOS towards glycolysis is regarded as 
an important event in the activation process of LPS stimulated macrophages150 and 
monocytes151. Furthermore DC maturation is linked to a reduction in OXPHOS and 
increase in glycolysis152. In our experiments LPS treatment changed the metabolic profile 
of DCs in a similar manner. LPS diminished ROUTINE respiration, oxygen consumption 
related to ATP production and the capacity of the electron transfer system in DCs whereas 
lactate secretion was increased. HG treatment blocked the reduction in mitochondrial 
activity and diminished the increase in glycolysis. In line, we recently could show that 
HG triggers an increase in oxidative phosphorylation and reduces the glycolytic activity 
of human T cells 132. Our data are in line with a tolerogenic phenotype of HG-treated DCs 
as Malinarich stated that tolerogenic DCs are characterized by increased OXPHOS and 
reduced glycolysis152. Moreover, Malinarich and colleagues demonstrated that tolerogenic 
DCs displayed a poor immunogenic phenotype, with low levels of IFN-γ and IL-12p40 
production, and increased levels of IL-10 production. In addition to this, in transcriptomic 
studies of tolerogenic DCs, Malinarich and colleagues observed an upregulation of 
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differentially expressed genes involved in OXPHOS, mitochondrial dysfunction, mTOR 
and HIF signaling. While IL-12 was also suppressed in our HG-DCs, we detected only a 
slight increase in complex I and II. 
An impact of HG on OXPHOS has also been described in tumor cell lines. Here, IDH 
mutated cells have been shown to display increased OXPHOS activity 153,154. In our 
experiments exogenous application of HG to glioblastoma cell lines did not alter 
mitochondrial activity. Other publication describes  even a negative effect on respiration 
in IDH mutated cells and after addition of exoegenous HG. Chan and colleagues observed 
that D-HG inhibited mitochondrial cytochrome c oxidase (COX) activity in acute myeloid 
leukemia cells 155. Fu et al. reported an inhibition of respiration and ATP synthase in 
glioblastoma cells 156. Taken together, HG blocked the LPS induced decrease in 
mitochondrial respiratory activity and the increase in glycolysis. However, as blocking of 
mitochondrial respiration was not sufficient to increase IL-12 levels in the presence of 
HG in DCs, we conclude that additional mechanisms are involved.  
Mitochondria play an important role not only for ATP production but also in cellular 
calcium homeostasis. On the other hand calcium affects mitochondrial activity. To 
investigate the role of mitochondrial calcium flux on IL-12 production, we added CsA.  
Increased cytosolic calcium levels have been shown to reduce IL-12 secretion in 
macrophages 119. We speculated that HG leads to increased cytosolic calcium levels, 
thereby reducing IL-12 production. CsA is capable to increase the calcium storage 
capacity of mitochondria, thereby probably counter balancing the effect of HG.  
Notably, DCs treated with CsA and LPS showed an increase in IL-12 production in 
comparison to iDCs stimulated with LPS, nevertheless this increase was not statistically 
significant. CsA attenuated the suppressive effect of D-HG, but did not entirely rescue it. 
In line, CsA treatment could partially prevent the impact of HG on the LPS induced 
decline in respiration, although with some time delay.  
This delayed effect point towards an attenuation of the D-HG effect as the one observed 
in IL-12 levels. These results are contradictory to the effect observed by Huang and 
colleagues, where they demonstrated that CsA treated DCs show a reduced IL-12 
production 157. 
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5.5 Effect of HG on the RNA expression of Dendritic 
Cells  
In order to elucidate a more global effect of D-HG on DCs we performed RNAseq 
analyses. To our knowledge this is the first global gene expression analysis in DCs treated 
with D-HG. As a control DCs were incubated with Di-ketoglutarate, which is a structural 
closely related molecule but had no impact on IL-12 secretion.  
Three criteria were applied: First, genes that were significantly different in LPS-
stimulated DCs compared to untreated DCs. Second, genes that were significantly 
different in LPS+D-HG-treated DCs compared to LPS-stimulated DCs. Third, genes that 
were not significantly affected by Di-Keto treatment. Using these three criteria, only 6 
genes were differentially upregulated and 6 genes downregulated by D-HG.  
D-HG upregulated F2RL2, a member of a transmembrane receptor family that couple to 
G proteins158. F2RL2 gene encodes the Protease activated receptor 3 (PAR-3). PAR3 
directly dimerizes with PAR1 to induce a specific PAR1/Gα13-binding conformation that 
favors Gα13 activation 159. As previously mentioned, GPR109A and its ligand niacin were 
not involved in the reduction of IL-12 in our experiments, but this does not exclude that 
other G-proteins may be involved. HG-induced related changes in PAR-3 signalling could 
be involved in suppression of IL-12.  Agonist peptides of PAR-1 and PAR-4 but not 
PAR-3 hav been shown to induce IL-6 release from monocytes whereas IL-12 was not 
increased 160. In further experiments the impact of PAR-3 on DCs should be analyzed.  
In the present work HG also upregulated the gene , Bone Morphogenetic Protein 6 
(BMP6), which has been described to be upregulated by pro-inflammatory cytokines (IL-
17 and TNF-α) in rheumatoid arthritis synoviocytes 161. Also in a previous study by Varas 
and colleagues, the authors demonstrated that BMP signaling pathway are important for 
the regulation of CD4+ T-cell proliferation 162. Interestingly Maurer and colleagues 
described that BMP 7 inhibited the differentiation of human CD14+ monocytes to 
osteoclasts 163. Therefore it would be intersting to study the relation between disturbed 
DC differentiation by HG and BMP 6 levels during DC differentiation. 
Another gene upregulated by D-HG was C-X-C Motif Chemokine Receptor 5 (CXCR5). 
iDC express different chemokine recptors which regulate their migration in response to 
CCR5 ligands such as RANTES, MIP-1α and MIP-β. Maturation of DCs by LPS, TNF-α, 
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or CD40 ligation down-regulates CXCR5 expression164. Upregulated expression by HG is 
another marker for a disturbed DC differentiation.  
Another gene upregulated by D-HG was Myosin 1B (MYO1B). MYO1B is involved in 
neuronal development and function such as cell migration and vesicular transport. Little is 
known on its role in myeloid cells. However as MYO1B controls the formation of 
secretory granules it could probably be involved in the secretion of IL-12 in DCs 165.  
The plasminogen activator/plasmin system is an enzymatic cascade involved in the 
control of matrix turnover and thereby can regulate cell invasion and migration of tumor 
and immune cells.  
Plasminogen Activator, Tissue Type (PLAT) gene was also upregulated by D-HG 
treatment. PLAT gene encodes tissue-type plasminogen activator protein, involved in the 
breakdown of blood clots, which has been related with the secretion of IL-6 cytokine after 
a stroke event via NMDA receptors activation and upregulation of endothelin 1 (ET-1) 
and JNKmitogen-activated protein kinase (MAPK)166. In the present work, we found no 
effect on JNK pathway by the addition of D-HG, results that contradicts the data by 
Armstead and colleagues166.  
Another gene upregulated by D-HG effect was plasminogen activator inhibitor-2 
(SERPINB2), an inhibitor of urokinase plasminogen activator (uPA). Ponnala and 
collegues demonstrated in gliomas cells, that silencing of the uPA receptor induced a 
switch from glycolytic metabolism to oxidative phosphorylation (OXPHOS) and 
generated reactive oxygen species (ROS) predisposing glioma cells to mitochondrial outer 
membrane permeabilization167. These reports could point towards a possible relation 
between upregulation of OXPHOS by HG through inhibition of uPA.  
 
Next we analyzed genes downregulated after 24hrs of treatment with D-HG. Interestingly, 
we observed a downregulation of the IL-18 gene. The IL-18 gene encodes Interleukin-18 
(IL-18), a pro inflamatory cytokine,  which has a similar function as IL-12  168. 
Interleukin-18 is a member of IL-1 superfamily of cytokines. The main function is 
synergistically with IL-12 to induce Th1 differentiation and interferon-γ secretion. IL-18 
downregulation by D-HG could give a hint in direction of an immunosuppressive capacity 
of D-HG.  
Also downregulated was Long non-coding RNA LINC01619, which recently has been 
reported to regulate miR-27a/FOXO1 and induce endoplasmic reticulum stress-mediated 
podocyte injury in diabetic nephropathy. In diabetic rats and high glucose cultured 
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podocytes, LINC01619 triggered oxidative stress 169. This findings suggest that 
LINCO1619 downregulation in DCs could be a feedback mechanism to suppress D-HG-
induced oxidative stress.  
We also demonstrated a downregulation on Dynein heavy chain 11, axonemal (DNAH11). 
Mutations in the coding region of DNAH11 have been linked to primary ciliary 
dyskinesia, an autosomal recessive disorder that leads to chronic respiratory disorders 170 
and diabetic nephropathy171. Furthermore, mutations have been described in a minority of 
AML patients by Ahn and colleagues. They demonstrated a prevalence of IDH1 and 2 
Mutations after transplantation (16.5%), whereas the prevalence of DNAH11 mutations 
was just 1. 7% 172. The DNAH11 mutation was only associated with ASXL2 mutations 
but not with the IDH mutations excluding a link with higher HG levels. It is possible that 
high HG levels in IDH mutated AML downregulate DNAH11 independent of a mutation 
which could be analyzed in further investigations.  
 
 
 
Summary 
 
86 
 
6. Summary  
 
Tumor development is commonly associated with genetic alterations such as activation of 
oncogenes or the silencing of tumor suppressor genes. Recently point mutations in genes 
encoding isocitrate dehydrogenase (IDH) have gained substantial interest in glioma 
classification. IDH mutations are also frequently found in neoplasias including acute 
myeloid leukemia (AML). Mutated IDH aquires the function to produce the 
oncometabolite D-2-hydroxyglutarate (D-HG). D-HG levels in the tissue of glioma 
patients can reach concentrations up to 35mM. Nevertheless, little is known on the impact 
of D-HG on non-malignant human immune cells.  
In the present work, we compared the effect of both HG enantiomers, D-HG and L-2-
Hydroxyglutarate (L-HG) on dendritic cell (DC) maturation and activation, and found 
similar effects with both enantiomers. We also analyzed the impact of D-HG on the 
respiration of DCs and two glioblastoma cell lines.  
We found that D-HG was taken up by LPS-stimulated DCs. Furthermore, the presence of 
D-HG during maturation and activation of DCs strongly affected the production of IL-12. 
Especially when DCs were treated with D-HG during the entire maturation process, the 
IL-12 production was extremely reduced.  
To elucidate the mechanism by which D-HG modulates IL-12 production, we studied the 
principal components of the Toll-like receptor 4 signaling pathway involved in IL-12 p70 
production (NF-κB, HIF-α, PI3-kinase pathway components). However, we found no 
significant effect of D-HG treatment on any of these pathways after 1hr or 24hrs of 
incubation. As we found an increase of GPR109A expression after LPS stimulation, we 
studied a possible involvement of this receptor but found no significant relation between 
IL-12 production and the reported GPR109A ligand, niacin.  
Cyclic adenosine monophosphate (cAMP) has been described to be involved in DC 
function. We found significant reduction of IL-12 production by the treatment of DCs 
with cAMP and the cAMP-inducing-factor forskolin. However, due to technical problems, 
we could not detect cAMP in DCs. As several reports state a possible relation between 
cAMP signaling pathways and mitochondrial respiration, we analyzed the impact of D-
HG on mitochondrial respiration of LPS-stimulated DCs. We observed an inhibition of 
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routine respiration caused by LPS, whereas pre-treatment with D-HG blocked this LPS 
effect. As treatment with oligomycin and rotenone (inhibitors of mitochondrial 
respiration) did not recover IL-12 suppression, the impact of HG on respiration alone is 
not sufficient to explain the suppressive effect of HG.  
To further analyze the effect of D-HG on mitochondrial respiration we utilized an 
inhibitor of mitochondrial calcium efflux, cyclosporine A (CsA). We noticed an increase 
of IL-12 levels after CsA treatment compared with DCs activated without CsA treatment. 
Combination of CsA and D-HG in LPS-stimulated DCs partially rescued IL-12 levels 
caused by D-HG treatment. During high resolution respirometry studies we observed a 
delayed reduction of routine respiration 2hrs after CsA treatment. Also, we found a 
modest increase of respiratory chain complex expression in stimulated DCs treated with 
D-HG (complex I and II). Moreover, lactate secretion studies showed an increase of 
lactate levels by LPS. D-HG was able to block this increase. These observations point 
towards the capacity of D-HG to interfere with the metabolic shift from oxidative 
phosphorylation into glycolysis promoted by LPS. This could also explain the suppressive 
effect of D-HG on IL-12 production.  
IDH mutations are associated with glioma development and prognosis. Nevertheless the 
effect of D-HG on mitochondrial respiration of glioma cell lines is poorly documented. In 
the present work, we found no consistent effect on mitochondrial respiration by D-HG in 
two glioma cell lines.  
 
Furthermore, we investigated global effects of HG on DCs by RNAseq analyses. 
Surprisingly most genes were similarily regulated by HG and our control substance di-
ketoglutarate most likely due to its close structural similarity. Only 6 genes were 
upregulated and 3 genes were downregulated by HG. Further investigations have to be 
performed to investigate the link between the identified genes and DC function. 
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7. Zusammenfassung 
 
Tumoren werden durch Mutationen in Protoonkogenen und Tumorsurpressorgenen 
verursacht. Diese Mutationen führen entweder zur Aktivierung von Onkogenen oder zum 
Stilllegen von Tumorsupressorgenen. Aktuell wurden Punktmutationen im Gen der 
Isocitrat-Dehydrogenase (IDH) für die Klassifizierung von Gliomen beschrieben. IDH 
Mutationen werden neben dem Gliom, häufig in der Akuten myeloischen Leukämie 
gefunden. Durch die Mutation bekommt die IDH die Fähigkeit D-2-hydroxygluterat (D-
HG) zu produzieren. D-HG kann im Tumorgewebe von Gliom Patienten eine 
Konzentration bis zu 35mM erreichen. Der Effekt von D-HG auf humane Immunzellen ist 
bisher wenig untersucht.  
In dieser Arbeit wurde der Einfluss von D-HG auf die Reifung und Aktivierung von 
dendritischen Zellen (DCs) untersucht und mit der Wirkung des Enantiomers L-HG 
verglichen. Die Effekte beider Enantiomere waren vergleichbar. Außerdem wurde der 
Einfluss von D-HG auf die Atmung von DCs und zwei Glioblastom Zelllinien untersucht. 
Zuerst bestätigten wir das D-HG von LPS aktivierten DCs aufgenommen wird. Des 
Weiteren sahen wir eine stark reduzierte IL-12 Produktion in DCs, wenn D-HG während 
der Reifung präsent war.  
Um den Mechanismus des Effekts von D-HG auf die IL-12 Produktion zu analysieren, 
wurden zentrale Proteine des Toll-like Rezeptors (TLR) 4 Signalwegs, die bei der IL-12 
p70 Produktion beteiligt sind (NF-κB, HIF-α, PI3-kinase Signalweg), untersucht. Jedoch 
zeigte D-HG weder nach 1 Stunde noch nach 24h einen signifikanten Effekt auf die 
Aktivität oder Menge der untersuchten Proteine. Die Aktivierung von DCs mit LPS führte 
auch zu einer erhöhten Expression des G Protein gekoppelten Rezeptors GPR109A, aber 
auch hier konnte kein Zusammenhang mit dem IL-12 supprimierenden Effekt von D-HG 
hergestellt werden, da Niacin, ein GPR109A Ligand keinen Einfluss auf die IL-12 
Produktion hatte. 
Cyclisches Adenosinmonophosphat (cAMP) ist ein wichtiger sekundärer Botenstoff der 
als wichtig für die DC Funktion beschrieben wurde. Die Behandlung von DCs mit cAMP 
und Foskolin, einem cAMP-induzierenden Faktor führte zu einer signifikanten Reduktion 
der IL-12 Produktion. Einige Arbeitsgruppen beschreiben einen Zusammenhang zwischen 
cAMP Signalweg und der Atmung, deshalb wurde der des Weiteren der Einfluss von D-
HG auf die Atmung von DCs untersucht. LPS reduzierte die basale Atmung, diese 
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Reduktion konnte durch eine D-HG Vorinkubation blockiert werden. Allerdings kam es 
durch die Behandlung mit Oligomycin und Rotenon (Inhibitoren der Atmungskette) zu 
keiner Erhöhung der verminderten IL-12 Produktion.  
Um den Einfluss von D-HG auf die Atmung weiter zu charakterisieren wurden DCs mit 
Cyclosporin A (CsA) behandelt. CsA inhibiert den Transport von Calcium aus dem 
Mitochondrium. CsA erhöhte die IL-12 Produktion im Vergleich zur IL-12 Produktion 
nach Aktivierung mit LPS alleine. Auch in Kombination mit D-HG war die IL-12 
Produktion höher als nur mit D-HG. CsA führte außerdem zu einer verspäteten Reduktion 
der basalen Atmung nach 2 Stunden.  
Des Weiteren wurde die Expression der Atmungsketten Komplexe mittels Western Blot 
untersucht. Komplex I und II waren vermehrt in D-HG behandelten DCs messbar. Um 
den Effekt von D-HG auf den Metabolismus weiter zu untersuchen wurde die 
Laktatkonzentration im Überstand bestimmt. LPS führte zu einer Erhöhung der 
Laktatlevel, D-HG war in der Lage diese Erhöhung zu Blockieren. Diese Beobachtung 
weist darauf hin, dass D-HG fähig war, die durch LPS induzierte metabolische 
Umstellung von oxidative Phosphorylierung hin zur Glykolyse zu beeinflussen. Dies 
könnte auch die verminderte IL-12 Produktion erklären, da die metabolische Umstellung 
für die Aktivierung eine Rolle spielen könnte. 
Weiterhin wurde der Effekt von D-HG auf die Atmung von Gliom Zelllinien untersucht. 
In dieser Arbeit fanden wir keinen konsistenten Effekt von D-HG auf die Atmung von 
U87 Zellen und TP365,  
 
In weiteren Analysen wurde mittels RNAseq Effekte von HG auf die Genexpression von 
DCs untersucht. Es zeigte sich, dass HG und di-Ketoglutarat weitestgehend vergleichbare 
Veränderungen in der Genexpression induzieren. Dies hängt wahrscheinlich damit 
zusammen, dass diese beiden Substanzen chemisch eng verwandt sind. Allerdings wurden 
durch HG 6 Gene hochreguliert und 3 Gene supprimiert, die nicht durch Ketoglutarat 
reguliert waren. In weiteren Untersuchungen muss der Zusammenhang zwischen der DC 
Funktion und diesen Genen analysiert werden. 
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9. Index 
 
9.1 Effect of D-HG and α-Ketoglutarate on the RNA 
expression of Dendritic Cells 
In order to elucidate the possible competitive effect of α-Ketoglutarate (Di-Keto) and D-
HG on gene expression, we differentiated dendritic cells from monocytes, and treated 
them with 100ng/ml LPS, 10mM D-HG or 10mM Di-Keto. Genes shown in the following 
tables satisfied 2 criteria. First, genes were significantly different in LPS-stimulated DCs 
compared to untreated DCs. Second, genes were significantly different in LPS-stimulated 
DCs compared to DCs treated either with D-HG or Di-Keto. 
   Table 9.1 Top 30 genes up regulated by the effect of D-HG and Di-Keto.  
 
 
DCs RNA Seq 
  Up-Regulated 
with D-HG P Value FDR transcript type 
foldchange/
pvalue 
1 MMP1 3.59E-40 4.50E-36 protein_coding 1 
2 MYO1B 1.99E-26 1.25E-22 protein_coding 1 
3 SLC39A14 1.61E-25 6.74E-22 protein_coding 1 
4 AKR1B1 5.44E-25 1.71E-21 protein_coding 1 
5 ALDH1A2 5.92E-22 1.48E-18 protein_coding 1 
6 SERPINE1 1.02E-19 1.83E-16 protein_coding 1 
7 CRISPLD2 6.59E-19 1.03E-15 protein_coding 1 
8 SERPINB2 5.30E-16 6.64E-13 protein_coding 1 
9 FLT1 6.00E-16 6.84E-13 protein_coding 1 
10 HBEGF 6.60E-15 6.89E-12 protein_coding 1 
11 MRPS6 6.20E-14 5.97E-11 protein_coding 1 
12 MICAL2 1.09E-13 9.09E-11 protein_coding 1 
13 IL17RB 2.08E-13 1.63E-10 protein_coding 1 
14 SLC5A3 2.84E-13 2.10E-10 protein_coding 1 
15 BMP6 3.14E-13 2.14E-10 protein_coding 1 
16 SNORD3A 3.59E-12 2.05E-09 snoRNA 1 
17 TM4SF1 5.90E-12 3.22E-09 protein_coding 1 
18 PTGES 7.52E-12 3.93E-09 protein_coding 1 
19 EGLN3 1.55E-11 7.49E-09 protein_coding 1 
20 TMEM132A 2.31E-11 1.07E-08 protein_coding 1 
21 PLAT 2.72E-11 1.22E-08 protein_coding 1 
22 IL23A 4.01E-11 1.73E-08 protein_coding 1 
23 VDR 5.47E-11 2.19E-08 snoRNA 1 
24 SSTR2 5.59E-11 2.19E-08 protein_coding 1 
25 SNORD3C 5.31E-11 2.19E-08 protein_coding 1 
26 TGM2 6.48E-11 2.46E-08 protein_coding 1 
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27 LHFP 8.88E-11 3.27E-08 protein_coding 1 
28 FERMT2 9.74E-11 3.49E-08 protein_coding 1 
29 NKX3-1 1.05E-10 3.66E-08 protein_coding 1 
30 PTGS2 1.22E-10 4.14E-08 protein_coding 1 
 
More than 200 genes were upregulated by the effect of D-HG and Di-Keto, whereas only 
6 genes were significantly affected by the specifically effect of D-HG. Which could 
represent a co-activity between α-Ketoglutarate and D-HG. Next we analyzed genes 
downregulated by the effect of D-HG/Di-Keto. 
 
   Table 9.2 Top 30 genes downregulated by the effect of D-HG and Di-Keto. 
 
DCs RNA Seq 
 Down Regulated with 
D-HG P Value FDR transcript type 
foldchange/
pvalue 
CXCL13 6.29E-21 1.31E-17 protein_coding -1 
RP11-107E5.3 7.33E-17 1.02E-13 TEC -1 
TNNT2 7.81E-14 6.99E-11 protein_coding -1 
CXCL11 3.25E-13 2.14E-10 protein_coding -1 
RP3-368A4.6 1.01E-12 6.27E-10 protein_coding -1 
ANKRD36C 1.05E-12 6.27E-10 sense_intronic -1 
ADTRP 1.40E-11 7.00E-09 protein_coding -1 
MT1JP 3.90E-10 1.16E-07 
transcribed_unprocess
ed_pseudogene -1 
MARCO 1.04E-09 2.90E-07 protein_coding -1 
SEMA3A 1.42E-09 3.78E-07 protein_coding -1 
RP11-625I7.1 2.26E-09 5.56E-07 lincRNA -1 
IDO2 2.20E-09 5.56E-07 protein_coding -1 
DST 3.87E-09 9.15E-07 protein_coding -1 
RP11-81H14.1 4.90E-09 1.12E-06 lincRNA -1 
C12orf79 6.06E-09 1.36E-06 protein_coding -1 
TTN-AS1 7.15E-09 1.55E-06 antisense -1 
ODC1 1.04E-08 2.16E-06 protein_coding -1 
MALAT1 1.26E-08 2.58E-06 protein_coding -1 
CCL23 1.54E-08 3.11E-06 protein_coding -1 
DNAH11 1.87E-08 3.67E-06 protein_coding -1 
CD163 1.87E-08 3.67E-06 protein_coding -1 
TRAF5 3.95E-08 7.49E-06 protein_coding -1 
RP11-519G16.3 6.95E-08 1.26E-05 antisense -1 
CEMIP 1.17E-07 1.99E-05 protein_coding -1 
LINC01539 1.37E-07 2.30E-05 lincRNA -1 
VPS13A 1.54E-07 2.48E-05 protein_coding -1 
IL18 2.17E-07 3.24E-05 protein_coding -1 
ZNF260 2.25E-07 3.32E-05 protein_coding -1 
PSMD6-AS2 2.33E-07 3.39E-05 antisense -1 
ZNF844 3.64E-07 4.86E-05 protein_coding -1 
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More than 190 genes were downregulated by the effect of D-HG and Di-Keto, whereas 
only 6 genes were significantly affected by the specifically effect of D-HG.  
More experiments to confirm these results should be performed, and a new classification 
criteria could be useful to analize the specific effects of Di-Keto and D-HG in gene 
expression. 
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